206 results on '"M. Fidler"'
Search Results
2. Alberta Childhood Cancer Survivorship Research Program
- Author
-
Andrew Harper, Fiona Schulte, Gregory M. T. Guilcher, Tony H. Truong, Kathleen Reynolds, Maria Spavor, Natalie Logie, Joon Lee, and Miranda M. Fidler-Benaoudia
- Subjects
childhood cancer ,pediatric cancer ,survivorship ,epidemiology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Adverse outcomes after childhood cancer have been assessed in a range of settings, but most existing studies are historical and ascertain outcomes only after 5-year survival. Here, we describe the Alberta Childhood Cancer Survivorship Research Program and its foundational retrospective, population-based cohort of Albertan residents diagnosed with a first primary neoplasm between the ages of 0 and 17 years from 1 January 2001 to 31 December 2018. The cohort was established in collaboration with the Alberta Cancer Registry and Cancer in Young People in Canada program and has been linked to existing administrative health databases and patient-reported outcome questionnaires. The cohort comprised 2580 survivors of childhood cancer, 1379 (53.4%) of whom were 5-year survivors. Approximately 48% of the cohort was female, 47% of the cohort was diagnosed between 0 and 4 years of age, and the most frequent diagnoses were leukemias (25.4%), central nervous system tumors (24.0%), and lymphomas (14.9%). Detailed treatment information was available for 1741 survivors (67.5%), with manual abstraction ongoing for those with missing data. By the study exit date, the median time since diagnosis was 5.5 years overall and 10.4 years for 5-year survivors. During the follow-up time, 82 subsequent primary cancers were diagnosed, 20,355 inpatient and 555,425 ambulatory/outpatient events occurred, 606,773 claims were reported, and 437 survivors died. The results from this research program seek to inform and improve clinical care and reduce cancer-related sequelae via tertiary prevention strategies.
- Published
- 2023
- Full Text
- View/download PDF
3. Trends in the Incidence of Cancer Among Adolescent and Young Adults in Alberta, 1983–2017: A Population-Based Study Using Cancer Registry Data
- Author
-
Andrew S. Harper, Ruth L. Diaz, Samantha N.R. Cortez, Lorraine Shack, Khalid Amin, Jingyu (Vickey) Bu, Ronald D. Barr, and Miranda M. Fidler-Benaoudia
- Subjects
Oncology ,Pediatrics, Perinatology and Child Health - Published
- 2023
4. Risk Factors for Primary Bone Cancer After Childhood Cancer: A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
- Author
-
Raoul C. Reulen, David L. Winter, Ibrahim Diallo, Cristina Veres, Damien Llanas, Rodrigue S. Allodji, Francesca Bagnasco, Edit Bárdi, Elizabeth A.M. Feijen, Daniela Alessi, Miranda M. Fidler-Benaoudia, Stine Høgsholt, Jop C. Teepen, Helena Linge, Nadia Haddy, Julianne Byrne, Ghazi Debiche, Desiree Grabow, Thorgerdur Gudmundsdottir, Romain Fauchery, Wael Zrafi, Gisela Michel, Hilde Øfstaas, Peter Kaatsch, Giao Vu-Bezin, Helen Jenkinson, Melanie Kaiser, Roderick Skinner, Trevor Cole, Nicolas Waespe, Grit Sommer, Susanne Nordenfelt, Momcilo Jankovic, Tuomas Lähteenmäki Taalas, Milena M. Maule, Helena J.H. van der Pal, Cécile M. Ronckers, Flora E. van Leeuwen, Judith L. Kok, Monica Terenziani, Maria Winther Gunnes, Thomas Wiebe, Carlotta Sacerdote, Zsuzsanna Jakab, Riccardo Haupt, Päivi M. Lähteenmäki, Lorna Zadravec Zaletel, Claudia E. Kuehni, Jeanette Falck Winther, Leontien C.M. Kremer, Lars Hjorth, Florent de Vathaire, and Michael M. Hawkins
- Subjects
Cancer Research ,Oncology - Abstract
PURPOSE Radiation to the bone and exposure to alkylating agents increases the risk of bone cancer among survivors of childhood cancer, but there is uncertainty regarding the risks of bone tissue radiation doses below 10 Gy and the dose-response relationship for specific types of chemotherapy. METHODS Twelve European countries contributed 228 cases and 228 matched controls to a nested case-control study within a cohort of 69,460 5-year survivors of childhood cancer. Odds ratios (ORs) of developing bone cancer for different levels of cumulative radiation exposure and cumulative doses of specific types of chemotherapy were calculated. Excess ORs were calculated to investigate the shape and extent of any dose-response relationship. RESULTS The OR associated with bone tissue exposed to 1-4 Gy was 4.8-fold (95% CI, 1.2 to 19.6) and to 5-9 Gy was 9.6-fold (95% CI, 2.4 to 37.4) compared with unexposed bone tissue. The OR increased linearly with increasing dose of radiation ( Ptrend < .001) up to 78-fold (95% CI, 9.2 to 669.9) for doses of ≥40 Gy. For cumulative alkylating agent doses of 10,000-19,999 and ≥20,000 mg/m2, the radiation-adjusted ORs were 7.1 (95% CI, 2.2 to 22.8) and 8.3 (95% CI, 2.8 to 24.4), respectively, with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide. Other cytotoxics were not associated with bone cancer. CONCLUSION To our knowledge, we demonstrate—for the first time—that the risk of bone cancer is increased 5- to 10-fold after exposure of bone tissue to cumulative radiation doses of 1-9 Gy. Alkylating agents exceeding 10,000 mg/m2 increase the risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide. These substantially elevated risks should be used to develop/update clinical follow-up guidelines and survivorship care plans.
- Published
- 2023
5. Systematic reviewers' perspectives on replication of systematic reviews: A survey
- Author
-
Phi‐Yen Nguyen, Joanne E. McKenzie, Daniel G. Hamilton, David Moher, Peter Tugwell, Fiona M. Fidler, Neal R. Haddaway, Julian P. T. Higgins, Raju Kanukula, Sathya Karunananthan, Lara J. Maxwell, Steve McDonald, Shinichi Nakagawa, David Nunan, Vivian A. Welch, and Matthew J. Page
- Published
- 2023
6. Systematic reviewers' perspectives on sharing review data, analytic code, and other materials: A survey
- Author
-
Phi‐Yen Nguyen, Joanne E. McKenzie, Daniel G. Hamilton, David Moher, Peter Tugwell, Fiona M. Fidler, Neal R. Haddaway, Julian P. T. Higgins, Raju Kanukula, Sathya Karunananthan, Lara J. Maxwell, Steve McDonald, Shinichi Nakagawa, David Nunan, Vivian A. Welch, and Matthew J. Page
- Published
- 2023
7. Psychiatric Disorder Incidence Among Adolescents and Young Adults Aged 15-39 With Cancer: Population-Based Cohort
- Author
-
Brianna K Rosgen, Stephana J Moss, Kirsten M Fiest, Sarah McKillop, Ruth L Diaz, Ronald D Barr, Scott B Patten, Julie Deleemans, and Miranda M Fidler-Benaoudia
- Subjects
Cancer Research ,Oncology - Abstract
Background Adolescent and young adult (AYA) cancer survivors face physical and psychological sequelae related to having cancer decades after treatment completion. It is unclear if AYA cancer survivors are at increased risk for late psychiatric disorders. Methods We used the Alberta AYA Cancer Survivor Study that includes 5-year survivors of cancer diagnosed at age 15-39 years during 1991 to 2013. The primary outcome was incidence of psychiatric disorder (composite outcome) including anxiety, depressive, trauma- and stressor-related, psychotic, and substance use disorders that were identified using coding algorithms for administrative health databases. A validated coding algorithm identified people who experienced a suicide attempt or event of self-harm. Secondary outcomes were incidences of diagnoses by type of psychiatric disorder. Results Among 12 116 AYA 5-year cancer survivors (n = 4634 [38%] males; n = 7482 [62%] females), 7426 (61%; n = 2406 [32%] males; n = 5020 [68%] females) were diagnosed with at least 1 of 5 psychiatric disorders occurring at least 3 years after cancer diagnosis. Survivors of all cancer types were most often diagnosed with anxiety (males: 39.0%, 95% confidence interval [CI] = 37.6% to 40.4%; females: 54.5%, 95% CI = 53.3% to 55.6%), depressive (males: 32.7%, 95% CI = 31.3% to 34.0%; females: 47.0%, 95% CI = 45.8% to 48.1%), and trauma- and stressor-related disorders (males: 13.5%, 95% CI =12.5% to 14.5%; females: 22.5%, 95% CI = 21.6% to 23.5%). Conclusions Anxiety, depressive, and trauma- and stressor-related disorders are common among 5-year survivors of AYA cancer. Primary, secondary, or tertiary preventive strategies for AYAs diagnosed with cancer, particularly at an early age, are needed to mitigate risk of potentially severe outcomes because of psychiatric disorders.
- Published
- 2022
8. High Utility of the 1st Metatarsal Phalangeal Joint Fusion
- Author
-
Mark A. Prissel, Roberto Brandão, Michael D. Dujela, Corey M. Fidler, Travis Langan, and Christopher F. Hyer
- Subjects
Arthritis, Rheumatoid ,Metatarsophalangeal Joint ,Foot Deformities, Acquired ,Arthrodesis ,Humans ,Orthopedics and Sports Medicine ,Surgery ,Metatarsal Bones - Abstract
Fusion of the first metatarsophalangeal joint has been used by foot and ankle surgeons as a reproducible and useful means of treating end-stage arthritis of the great toe. However, the overall utility and successful outcomes of this procedure have led to its incorporation into the treatment of more significant bunion deformities, reconstruction forefoot, and salvage procedures. The authors review surgical fixation methods, offer insightful technical pearls for challenging cases and share examples of complex reconstructive and salvage procedures.
- Published
- 2022
9. Low dose computed tomography of the lung for detection and grading of interstitial lung disease: A systematic simulation study
- Author
-
M. Durand, Lee M. Fidler, S. Ley, H. Schenk, Shane Shapera, Shikha Mittoo, Narinder Paul, and T. Marras
- Subjects
Male ,Pulmonary and Respiratory Medicine ,Simulation study ,Image quality ,Low-dose ,Computed tomography ,Radiation Dosage ,Sensitivity and Specificity ,Interstitial Lung Disease ,03 medical and health sciences ,Computed Tomography ,0302 clinical medicine ,Image Processing, Computer-Assisted ,Humans ,Medicine ,Computer Simulation ,030212 general & internal medicine ,Honeycombing ,Lung ,Grading (tumors) ,lcsh:RC705-779 ,medicine.diagnostic_test ,business.industry ,Low dose ,Interstitial lung disease ,lcsh:Diseases of the respiratory system ,Middle Aged ,Radiation Exposure ,medicine.disease ,Respiratory Function Tests ,medicine.anatomical_structure ,030228 respiratory system ,Associated image ,Female ,Diagnostic performance ,Lung Diseases, Interstitial ,Noise ,Tomography, X-Ray Computed ,business ,Nuclear medicine - Abstract
Purpose HRCT is the preferred imaging technique to evaluate Interstitial-Lung-Disease. Optimal Low-Dose-Computed-Tomography protocol for monitoring ILD with lowest radiation dose and optimal diagnostic accuracy and image quality unknown. Methods 28 Patients underwent HRCT. Image reconstructions with varying combinations of tube current (50mA, 20mA, 15 mA, 10mA) and image-thickness/increment (1/1mm, 2/2mm, 3/2.4mm, 5/4mm) were simulated from raw data. 448 CTs evaluated by 2 readers on image quality and ILD-specific features (ground glass opacification (ggo), honeycombing (hc), reticulation (ret)). Results Reduced dose settings with 20 mA did not show any significant difference to standard dose settings for all parameters in reader 1, while results were significantly altered in reader 2. Slice thickness did not significantly influence rating of typical ILD features like ggo, hc, ret or total disease extent. The correct differentiation between UIP and NSIP could be made on all dose settings and with all slice thickness. It was even found, that an increased slice thickness can compensate for the noise associated image quality degradation. Overall, for ggo detection a combination of 20 mA and 3 or 5 mm slice thickness was not different to the original evaluation. Conclusions Assessment of ILD specific CT features down to 20 mA and a slice thickness of 3 or 5 mm is feasible.
- Published
- 2021
10. Clinical outcomes associated with computed tomography‐based body composition measures in lung transplantation: a systematic review
- Author
-
Andrei Vagaon, Lee M. Fidler, John Michael Nicholson, Camila E. Orsso, K. Chohan, Brenawen Elangeswaran, Sunita Mathur, Sahar Nourouzpour, Dmitry Rozenberg, Ani Orchanian-Cheff, and Lianne G. Singer
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Primary Graft Dysfunction ,Lumbar vertebrae ,030230 surgery ,Body Mass Index ,03 medical and health sciences ,0302 clinical medicine ,Intensive care ,medicine ,Humans ,Lung transplantation ,Muscle, Skeletal ,Adiposity ,Mechanical ventilation ,Transplantation ,Lung ,business.industry ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Sarcopenia ,Body Composition ,Female ,030211 gastroenterology & hepatology ,Radiology ,Tomography, X-Ray Computed ,business ,Body mass index ,Lung Transplantation - Abstract
Computed tomography (CT) is gaining increased recognition in the assessment of body composition in lung transplant (LTx) candidates as a prognostic marker of post-transplant outcomes. This systematic review was conducted to describe the methodology of CT measures of body composition used in LTx patients and its association with post-transplant outcomes. Six databases were searched (inception-April 2020) for studies of adult LTx patients with thoracic or abdominal CT measures [muscle cross-sectional area (CSA) and/or adiposity]. Thirteen articles were included with 1911 LTx candidates, 58% males, mean age range (48-61 years) and body mass index of 21.0-26.1 kg/m2 . Several methods were utilized using thoracic or abdominal CT scans to assess skeletal muscle (n = 11) and adiposity (n = 4) at various anatomic locations (carina, thoracic, and lumbar vertebrae), differing muscle groups, and adipose tissue compartments. Low muscle mass was associated with adverse outcomes in 6/11 studies, including longer mechanical ventilation days (n = 2), intensive care (n = 2) and hospital stay (n = 2), and mortality (n = 4). Greater subcutaneous and mediastinal fat were associated with increased risk of primary graft dysfunction (n = 2), but implications of adiposity on survival were variable across four studies. Further standardization of CT body composition assessments is needed to assess the prognostic utility of these measures on LTx outcomes.
- Published
- 2020
11. Beaming in Charcot Arthropathy- Intramedullary Fixation for Complicated Reconstructions
- Author
-
Corey M. Fidler DPM, Benjamin C. Watson DO, Christopher W. Reb DO, and Christopher F. Hyer DPM, MS, FACFAS
- Subjects
Orthopedic surgery ,RD701-811 - Abstract
Category: Midfoot/Forefoot Introduction/Purpose: In the modern treatment of Charcot neuroarthropathy, beam screw fixation is an attractive alternative to plate and screw fixation because it minimizes the required exposure for implantation and supports the longitudinal columns of the foot from the inside out as a rigid yet load-sharing construct. Oversized implants risk metatarsal fracture and undersized implants risk implant fracture or impaired healing from mechanical instability. Our review of the scientific literature identified a lack of evidence regarding the aspects of metatarsal intramedullary canal morphology relevant to beam screw fixation. The purpose of the present study was to qualitatively and quantitatively describe metatarsal diaphyseal morphology. Methods: Twenty fresh-frozen adult cadaveric below knee specimens were utilized to assess the size and shape of the diaphysis of metatarsals 1-4. There were 10 male and 10 female specimens with a mean age of 75.8 years. No limbs had outward signs of prior injury/surgery, radiographic signs of Charcot neuroarthropathy or previous fracture. Metatarsals 1-4 were excised, cleaned of all soft tissue and then axially transected at the point of most narrow external diameter. The diaphyseal canal shape was categorized as round, oval, triangular, or pear. The widest distance between two endosteal cortical surfaces was measured. Results: Triangular endosteal canals were only found in the 1st metatarsal whereas the remainder of metatarsals canals were largely round or oval. The mean diameter of the 1st metatarsal was 9.08 ± 1.26 mm. The mean diameter of the 2nd metatarsal was 4.72 ± 0.82 mm. The mean diameter of the 3rd metatarsal was 4.53 ± 0.88 mm. The mean diameter of the 4th metatarsal was 4.51 ± 1.10 mm. Conclusion: Intramedullary fixation by internal beaming of the columns of the foot can provide anatomical alignment with stabile fixation in cases of patients with Charcot arthropathy. Our study has given the smallest average diameter for metatarsals one through 4. This data is helpful when determining what size fixation to choose to achieve the maximum screw-endosteal purchase for column beaming in Charcot reconstructions.
- Published
- 2016
- Full Text
- View/download PDF
12. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study
- Author
-
Noah Escandor, Hyuna Sung, Emily Heer, Valerie McCormack, Miranda M Fidler-Benaoudia, and Andrew Harper
- Subjects
medicine.medical_specialty ,030231 tropical medicine ,Population ,Breast Neoplasms ,Global Health ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Incidence trends ,medicine ,Humans ,In patient ,030212 general & internal medicine ,skin and connective tissue diseases ,education ,education.field_of_study ,Postmenopausal women ,business.industry ,Obstetrics ,lcsh:Public aspects of medicine ,Incidence ,Incidence (epidemiology) ,lcsh:RA1-1270 ,General Medicine ,Middle Aged ,medicine.disease ,Postmenopause ,Population based study ,Premenopause ,Premenopausal breast cancer ,Female ,business - Abstract
Summary Background Breast cancer has distinct causes, prognoses, and outcomes and effects in patients at premenopausal and postmenopausal ages. We sought to assess the global burden and trends in breast cancer by menopausal status. Methods We did a population-based analysis of global breast cancer incidence and mortality among premenopausal and postmenopausal women. Menopausal status was defined using age as a proxy, whereby breast cancer cases or deaths at age 50 years or older were regarded as postmenopausal. Age-standardised breast cancer incidence and mortality in 2018 were calculated using GLOBOCAN data. Incidence trends for 1998–2012 were assessed in 44 populations from 41 countries using the Cancer in Five Continents plus database, by calculating the annual average percent change. Findings Approximately 645 000 premenopausal and 1·4 million postmenopausal breast cancer cases were diagnosed worldwide in 2018, with more than 130 000 and 490 000 deaths occurring in each menopausal group, respectively. Proportionally, countries with a low UNDP human development index (HDI) faced a greater burden of premenopausal breast cancer for both new cases and deaths compared with higher income countries. Countries with a very high HDI had the highest premenopausal and postmenopausal breast cancer incidence (30·6 and 253·6 cases per 100 000, respectively), whereas countries with low and medium HDI had the highest premenopausal and postmenopausal mortality, respectively (8·5 and 53·3 deaths per 100 000, respectively). When examining breast cancer trends, we noted significantly increasing age-standardised incidence rates (ASIRs) for premenopausal breast cancer in 20 of 44 populations and significantly increasing ASIRs for postmenopausal breast cancer in 24 of 44 populations. The growth exclusively at premenopausal ages largely occurred in high-income countries, whereas the increasing postmenopausal breast cancer burden was most notable in countries under transition. Interpretation We provide evidence of a rising burden of both premenopausal and postmenopausal breast cancer worldwide. Although early diagnosis and access to treatment remain crucial in low-income and middle-income countries, primary prevention efforts seeking to decrease exposure to known breast cancer risk factors are warranted in all world regions to curb the future breast cancer burden. Funding None.
- Published
- 2020
13. International Trends in the Incidence of Cancer Among Adolescents and Young Adults
- Author
-
A. Lindsay Frazier, Sumit Gupta, Yibing Ruan, Ronald D. Barr, Jacques Ferlay, Miranda M Fidler-Benaoudia, Andrew Harper, and Eva Steliarova-Foucher
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Population ,Global Health ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Epidemiology ,medicine ,Humans ,Young adult ,education ,Thyroid cancer ,030304 developmental biology ,Cervical cancer ,0303 health sciences ,education.field_of_study ,business.industry ,Incidence ,Incidence (epidemiology) ,Age Factors ,Cancer ,Articles ,medicine.disease ,Confidence interval ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Demography - Abstract
Background Although adolescent and young adult (AYA) cancers represent a unique spectrum of malignancies, epidemiological studies of cancer incidence often group AYAs together with younger or older populations, obscuring patterns specific to this population. Methods We examined AYA cancer incidence trends in 41 countries over a 15-year period using the CI5plus database. Truncated age-standardized incidence rates were calculated and the annual percentage change was assessed, with statistical significance corresponding to a 95% confidence interval that does not include zero. Results From 1998 to 2012, the 41 included countries contributed a total of 1 846 588 cancer cases and 3.1 billion person-years among AYAs. Although statistically significant increases in the overall cancer burden were observed in 23 countries, the magnitude varied considerably, with the greatest increase in incidence observed in South Korea (annual percentage change2002–2012 = 8.5%, 95% confidence interval = 7.6% to 9.4%) due to thyroid cancer. Notable trends included sharp increases in the incidence of obesity-related malignancies among AYAs; indeed, statistically significant increases were observed among AYAs for 10 of 11 and 9 of 11 obesity-related cancer sites in the US and UK, respectively, with at least five obesity-related cancers statistically significantly increasing in Canada, Japan, South Korea, Australia, and the Netherlands. Other striking trends were noted for thyroid and testicular cancer, with statistically significantly increasing rates observed in 33 and 22 countries, respectively, whereas statistically significant declines in incidence were observed for smoking-related cancers, cervical cancer, and Kaposi sarcoma in many countries. Conclusions Our results highlight the future health-care needs related to treatment as well as the urgency for public health initiatives that can mitigate the increasing burden of cancer in AYAs.
- Published
- 2020
14. Lung cancer incidence in young women vs . young men: A systematic analysis in 40 countries
- Author
-
Lindsey A. Torre, Miranda M Fidler-Benaoudia, Freddie Bray, Jacques Ferlay, and Ahmedin Jemal
- Subjects
Adult ,Male ,Canada ,Cancer Research ,Lung Neoplasms ,Future studies ,Denmark ,Adenocarcinoma of Lung ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Risk Factors ,Germany ,Humans ,Medicine ,Registries ,Sex Distribution ,Lung cancer ,Netherlands ,business.industry ,Bronchial cancer ,Incidence ,Incidence (epidemiology) ,Bronchial Neoplasms ,Smoking ,Middle Aged ,medicine.disease ,United States ,Confidence interval ,Calendar period ,Oncology ,Cancer incidence ,030220 oncology & carcinogenesis ,Adenocarcinoma ,Female ,business ,New Zealand ,Demography - Abstract
Previous studies have reported converging lung cancer rates between sexes. We examine lung cancer incidence rates in young women vs. young men in 40 countries across five continents. Lung and bronchial cancer cases by 5-year age group (ages 30-64) and 5-year calendar period (1993-2012) were extracted from Cancer Incidence in Five Continents. Female-to-male incidence rate ratios (IRRs) and 95% confidence intervals (95%CIs) were calculated by age group and birth cohort. Among men, age-specific lung cancer incidence rates generally decreased in all countries, while in women the rates varied across countries with the trends in most countries stable or declining, albeit at a slower pace compared to those in men. As a result, the female-to-male IRRs increased among recent birth cohorts, with IRRs significantly greater than unity in Canada, Denmark, Germany, New Zealand, the Netherlands and the United States. For example, the IRRs in ages 45-49 year in the Netherlands increased from 0.7 (95% CI: 0.6-0.8) to 1.5 (95% CI: 1.4-1.7) in those born circa 1948 and 1963, respectively. Similar patterns, though nonsignificant, were found in 23 additional countries. These crossovers were largely driven by increasing adenocarcinoma incidence rates in women. For those countries with historical smoking data, smoking prevalence in women approached, but rarely exceeded, those of men. In conclusion, the emerging higher lung cancer incidence rates in young women compared to young men is widespread and not fully explained by sex differences in smoking patterns. Future studies are needed to identify reasons for the elevated incidence of lung cancer among young women.
- Published
- 2020
15. Long-Term Morbidity of Children Receiving Hematopoietic Stem Cell Transplant with Total Body Irradiation Conditioning for Hematologic Malignancies
- Author
-
A.F. Khan, Y. Xu, M. Fidler-Benaoudia, R. Diaz, and N. Logie
- Subjects
Cancer Research ,Radiation ,Oncology ,Radiology, Nuclear Medicine and imaging - Published
- 2022
16. LBA5 Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) from ADAURA
- Author
-
T. John, C. Grohe, J. Goldman, F. De Marinis, T. Kato, Q. Wang, J-H. Choi, B. Melotti, M. Fidler, L. Sainsbury, M. Stachowiak, S. Taggart, Y-L. Wu, M. Tsuboi, R.S. Herbst, and M. Majem Tarruella
- Subjects
Oncology ,Hematology - Published
- 2022
17. Myositis Antibodies and Interstitial Lung Disease
- Author
-
Manpreet Basuita and Lee M Fidler
- Subjects
Myositis ,Humans ,General Medicine ,respiratory system ,Lung Diseases, Interstitial ,Prognosis ,Dermatomyositis ,respiratory tract diseases ,Autoantibodies - Abstract
Background Interstitial lung disease (ILD) comprises a heterogeneous group of inflammatory and fibrotic conditions, often resulting in progressive lung function decline and increased mortality. Connective tissue disease (CTD) should be considered in all patients with ILD, as distinguishing between CTD-ILD and other forms of fibrotic lung disease has important therapeutic and prognostic implications. The idiopathic inflammatory myopathies (IIM) represent a CTD subtype of growing interest to ILD experts. The expansion and availability of myositis-specific and myositis-associated antibody testing has allowed for improved disease detection and characterization. Content In this review, we highlight the relationship between myositis antibodies and ILD. Select forms of IIM, such as the antisynthetase syndrome and clinically amyopathic dermatomyositis can present with rapidly progressive ILD, warranting timely disease diagnosis and management. Disease phenotypes, prevalence, laboratory testing, prognosis, and management strategies are described according to select myositis antibodies. Summary Myositis antibodies provide valuable information for clinicians managing patients with ILD. This review aims to increase awareness of their role in disease detection, pathophysiology, and possibly therapeutics.
- Published
- 2021
18. Data Resource Profile: The Alberta Adolescent and Young Adult Cancer Survivor Study
- Author
-
Khalid B Amin, Ruth L. Diaz, Michael J Lang, Jan-Willem Henning, Andrew Harper, Stephana J Moss, Natalie Logie, Fiona Schulte, Sarah J. McKillop, and Miranda M Fidler-Benaoudia
- Subjects
Gerontology ,Cancer survivor ,Resource (biology) ,Adolescent ,Epidemiology ,business.industry ,General Medicine ,Alberta ,Young Adult ,Cancer Survivors ,Neoplasms ,Quality of Life ,Medicine ,Humans ,Young adult ,business - Published
- 2021
19. Hospitalizations in Sarcoidosis: A Cohort Study of a Universal Healthcare Population
- Author
-
Matthew B. Stanbrook, Teresa To, Meyer Balter, Andrea S. Gershon, Jolene H. Fisher, and Lee M. Fidler
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,medicine.medical_specialty ,Adolescent ,Sarcoidosis ,Population ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Health care ,medicine ,Humans ,030212 general & internal medicine ,education ,Ontario ,education.field_of_study ,business.industry ,medicine.disease ,Hospitalization ,030228 respiratory system ,Family medicine ,Universal Health Care ,Female ,business ,Cohort study ,Healthcare system - Abstract
Rationale: Population-based analyses of hospitalization rates from countries with universal healthcare systems are lacking for patients with sarcoidosis. Objectives: To evaluate the long-term trend...
- Published
- 2021
20. Ophthalmologic assessments in patients with newly diagnosed sarcoidosis: An observational study from a universal healthcare system
- Author
-
Meyer Balter, Lee M. Fidler, Teresa To, Matthew B. Stanbrook, Radha P. Kohly, Andrea S. Gershon, and Jolene H. Fisher
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Canada ,Optometrists ,Time Factors ,Sarcoidosis ,Population health ,Newly diagnosed ,Diagnostic Techniques, Ophthalmological ,Logistic regression ,Health Services Accessibility ,Young Adult ,Sex Factors ,Medicine ,Humans ,In patient ,Young adult ,Aged ,Ophthalmologists ,business.industry ,Age Factors ,Middle Aged ,medicine.disease ,Universal Health Care ,Observational study ,Female ,business ,Delivery of Health Care ,Healthcare system - Abstract
Consensus guidelines for the management of sarcoidosis recommend screening eye examinations for all patients, even in those without ocular symptoms. We aimed to determine the proportion of sarcoidosis patients that complete ophthalmologic evaluations and factors associated with their performance.We identified patients with sarcoidosis using population health services data from Ontario, Canada between 1991 and 2019. Sarcoidosis was defined by ≥ 2 physician visits for sarcoidosis within a two-year period. Ophthalmologic evaluations were based on an optometrist or ophthalmologist visit within the year prior or two years following the diagnosis. We estimated correlations between the number of eye care professionals and proportion of sarcoidosis patients completing ophthalmologic assessments within regional health units. We evaluated for associations between ophthalmologic screening and patient characteristics using multivariable logistic regression.We identified 21,679 patients with sarcoidosis in Ontario. An ophthalmologic evaluation was performed in 14,751 (68.0%), with a similar number of individuals seeing ophthalmologists and optometrists (43.7% vs. 42.2%). The percentage of sarcoidosis patients undergoing an ophthalmologic evaluation within corresponding regional health units was moderately correlated with the number of practicing ophthalmologists (r = 0.64, p = 0.01), but not the number of optometrists (r = 0.08, p = 0.77). Patients who were older [OR per year 1.02 (95% CI 1.01-1.02), p 0.001] and female [OR 1.54 (95% CI 1.44-1.63), p 0.001] were more likely to complete ophthalmologic evaluations. Immigrants to Canada were less likely to undergo ophthalmologic assessments [OR 0.66 (95% CI 0.60-0.73), p 0.001].Most patients with sarcoidosis complete ophthalmologic examinations, though a substantial proportion does not. Young adults, men and immigrants were less likely to complete ophthalmologic evaluations. Limited access to ophthalmologists may at least in part explain why some sarcoidosis patients fail to complete ophthalmologic screening.
- Published
- 2021
21. Age disparities in stage‐specific colon cancer survival across seven countries: an International Cancer Benchmarking Partnership SURVMARK‐2 population‐based study
- Author
-
Hanna Tervonen, Freddie Bray, Anna Gavin, Bjørn Møller, Melina Arnold, Hadrien Charvat, Sophie Pilleron, Prithwish De, Oliver Bucher, Alana Little, Marianne Grønlie Guren, Aude Bardot, Linda Aagaard Thomsen, Paul M. Walsh, Christopher Jackson, Miranda M Fidler-Benaoudia, Sally Vernon, Isabelle Soerjomataram, Marzieh Araghi, and Dianne L. O'Connell
- Subjects
Male ,Canada ,Cancer Research ,medicine.medical_specialty ,Colorectal cancer ,Denmark ,Population ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,Registries ,education ,Socioeconomic status ,Aged ,Neoplasm Staging ,Aged, 80 and over ,education.field_of_study ,Norway ,business.industry ,Incidence ,Australia ,Cancer ,Middle Aged ,medicine.disease ,United Kingdom ,Confidence interval ,Cancer registry ,Population based study ,Benchmarking ,Oncology ,030220 oncology & carcinogenesis ,Colonic Neoplasms ,Female ,Colorectal Neoplasms ,business ,Ireland ,New Zealand ,Demography - Abstract
We sought to understand the role of stage at diagnosis in observed age disparities in colon cancer survival among people aged 50 to 99 years using population-based cancer registry data from seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway and the United Kingdom. We used colon cancer incidence data for the period 2010 to 2014. We estimated the 3-year net survival, as well as the 3-year net survival conditional on surviving at least 6 months and 1 year after diagnosis, by country and stage at diagnosis (categorised as localised, regional or distant) using flexible parametric excess hazard regression models. In all countries, increasing age was associated with lower net survival. For example, 3-year net survival (95% confidence interval) was 81% (80-82) for 50 to 64 year olds and 58% (56-60) for 85 to 99 year olds in Australia, and 74% (73-74) and 39% (39-40) in the United Kingdom, respectively. Those with distant stage colon cancer had the largest difference in colon cancer survival between the youngest and the oldest patients. Excess mortality for the oldest patients with localised or regional cancers was observed during the first 6 months after diagnosis. Older patients diagnosed with localised (and in some countries regional) stage colon cancer who survived 6 months after diagnosis experienced the same survival as their younger counterparts. Further studies examining other prognostic clinical factors such as comorbidities and treatment, and socioeconomic factors are warranted to gain further understanding of the age disparities in colon cancer survival.
- Published
- 2021
22. Utility of anti-neutrophil cytoplasmic antibody screening in idiopathic interstitial lung disease
- Author
-
Lee M, Fidler, Sonja, Kandel, Jolene H, Fisher, Shikha, Mittoo, and Shane, Shapera
- Subjects
Original Article: Clinical Research ,immune system diseases ,screening ,Interstitial lung disease ,cardiovascular diseases ,urologic and male genital diseases ,skin and connective tissue diseases ,vasculitis ,respiratory tract diseases - Abstract
Background: Interstitial lung disease (ILD) is an established manifestation of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Autoimmune serologic screening is recommended by international consensus guidelines during the evaluation of idiopathic ILD, but ANCA testing only on a case-by-case basis. Objective: We aimed to evaluate the role of ANCA screening in patients with idiopathic ILD. Methods: We performed a retrospective review of patients seen between September 2015 and April 2017 in the ILD clinic at Toronto General Hospital. Patients referred with confirmed or suspected connective tissue disease were excluded. Patient demographics, symptoms, chest imaging, and pulmonary function testing was collected. We performed descriptive statistics based on the presence of ANCAs and estimated operating characteristics for ANCA screening. Results: In total, 360 patients with idiopathic ILD were reviewed, 159 met study inclusion criteria and 4 (2.5%) tested positive for ANCAs. Two patients (1.2%) had elevated myeloperoxidase-ANCAs (MPO-ANCA) and 2 (1.2%) had elevated proteinase-3-ANCAs (PR3-ANCA). There were no significant associations between patient demographics and ANCAs. One patient (0.6%) with PR3-ANCAs was diagnosed with vasculitis following rheumatologic evaluation. Despite negative ANCA testing, 1 patient (0.6%) was diagnosed with vasculitis following rheumatologic evaluation. The sensitivity and specificity of ANCA screening for vasculitis in patients with ILD was calculated as 50% (95% CI, 1.3%-98.7%) and 98% (95%CI, 4.4-155.5) respectively. Negative and positive likelihood ratios were 0.5 (95%CI 0.1-2.0) and 26.2 (95%CI 4.4-155.5) respectively. Conclusion: ANCA screening in patients with idiopathic ILD rarely yields positive results. These results support an individualized approach to ANCA testing as opposed to widespread screening.
- Published
- 2020
23. Antacid Therapy in Idiopathic Pulmonary Fibrosis: A Swinging Pendulum
- Author
-
Lee M, Fidler and Kerri A, Johannson
- Subjects
Gastroesophageal Reflux ,Humans ,Antacids ,Idiopathic Pulmonary Fibrosis - Published
- 2020
24. Changes in Black-White Difference in Lung Cancer Incidence among Young Adults
- Author
-
Priti Bandi, Kimberly D. Miller, Stacey A. Fedewa, Ahmedin Jemal, Ann Goding Sauer, MaryBeth B Culp, Farhad Islami, Jiemin Ma, and Miranda M Fidler-Benaoudia
- Subjects
Cancer Research ,White (horse) ,business.industry ,Incidence (epidemiology) ,Smoking prevalence ,medicine.disease ,Article ,Confidence interval ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,medicine ,National Health Interview Survey ,030212 general & internal medicine ,Young adult ,AcademicSubjects/MED00010 ,Lung cancer ,business ,Birth cohort ,Demography - Abstract
Background We previously reported that lung cancer incidence between Blacks and Whites younger than 40 years of age converged in women and approached convergence in men. Whether this pattern has continued in contemporary young birth cohorts is unclear. Methods We examined 5-year age-specific lung cancer incidence in Blacks and Whites younger than 55 years of age by sex and calculated the Black-to-White incidence rate ratios (IRRs) and smoking prevalence ratios by birth cohort using nationwide incidence data from 1997 to 2016 and smoking data from 1970 to 2016 from the National Health Interview Survey. Results Five-year age-specific incidence decreased in successive Black and White men born since circa 1947 and women born since circa 1957, with the declines steeper in Blacks than Whites. Consequently, the Black-to-White IRRs became unity in men born 1967-1972 and reversed in women born since circa 1967. For example, the Black-to-White IRRs in ages 40-44 years born between 1957 and 1972 declined from 1.92 (95% confidence interval [CI] = 1.82 to 2.03) to 1.03 (95% CI = 0.93 to 1.13) in men and from 1.32 (95% CI = 1.24 to 1.40) to 0.71 (95% CI = 0.64 to 0.78) in women. Similarly, the historically higher sex-specific smoking prevalence in Blacks than Whites disappeared in men and reversed in women born since circa 1965. The exception to these patterns is that the incidence became higher in Black men than White men born circa 1977-1982. Conclusions The historically higher lung cancer incidence in young Blacks than young Whites in the United States has disappeared in men and reversed in women, coinciding with smoking patterns, though incidence again became higher in Black men than White men born circa 1977-1982.
- Published
- 2020
25. Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study
- Author
-
Elizabeth A.M. Feijen, Wael Salem Zrafi, Ibrahim Diallo, Lorna Zadravec Zaletel, Daniela Alessi, Rahel Kuonen, Thomas Wiebe, Eva-Maria Hau, Jeanette Falck Winther, Edit Bardi, Monica Terenziani, Francesca Bagnasco, Zsuzsanna Jakab, Julianne Byrne, Rodrigue M Allodji, Melanie Kaiser, Leontien C.M. Kremer, Hilde Øfstaas, Helena M. Linge, Michael M. Hawkins, Thorgerdur Gudmundsdottir, Lars Hjorth, Moncilo Jankovic, Chloe J Bright, Florent de Vathaire, Claudia E. Kuehni, Päivi M. Lähteenmäki, Stine Høgsholt, David L. Winter, Carlotta Sacerdote, Peter Kaatsch, Raoul C. Reulen, Joyeeta Guha, Miranda M Fidler-Benaoudia, Stanislaw Garwicz, Ghazi Debiche, Giao Vu-Bezin, Desiree Grabow, Riccardo Haupt, Cristina Veres, Nadia Haddy, Kwok Wong, Andrea Bautz, Jop C Teepen, Damien Llanas, Roderick Skinner, Finn Wesenberg, Flora E. van Leeuwen, and Cécile M. Ronckers
- Subjects
medicine.medical_specialty ,Colorectal cancer ,Population ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Epidemiology of cancer ,COLORECTAL CANCER SCREENING ,medicine ,Cumulative incidence ,030212 general & internal medicine ,Gastrointestinal cancer ,Family history ,education ,610 Medicine & health ,GASTROINTESTINAL CANCER ,COLORECTAL CANCER ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Gastroenterology ,medicine.disease ,030220 oncology & carcinogenesis ,Cohort ,CANCER EPIDEMIOLOGY ,business ,360 Social problems & social services - Abstract
BackgroundSurvivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.MethodsThe PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.Results427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors were at greatest risk (SIR 12.1; 95% CI 9.6 to 15.1; SIR 7.3; 95% CI 5.9 to 9.0, respectively). The cumulative incidence increased the most steeply with increasing age for WT survivors, reaching 7.4% by age 55% and 9.6% by age 60 years (1.0% expected based on general population rates). Regarding colorectal SPNs, WT and HL survivors were at greatest risk; both seven times that expected. By age 55 years, 2.3% of both WT (95% CI 1.4 to 3.9) and HL (95% CI 1.6 to 3.2) survivors had developed a colorectal SPN—comparable to the risk among members of the general population with at least two first-degree relatives affected.ConclusionsColonoscopy surveillance before age 55 is recommended in many European countries for individuals with a family history of colorectal cancer, but not for WT and HL survivors despite a comparable risk profile. Clinically, serious consideration should be given to the implementation of colonoscopy surveillance while further evaluation of its benefits, harms and cost-effectiveness in WT and HL survivors is undertaken.
- Published
- 2020
26. A Comparison of Late Mortality Among Survivors of Childhood Cancer in the United States and United Kingdom
- Author
-
David L. Winter, Michael M. Hawkins, Gregory T. Armstrong, Leslie L. Robison, Yutaka Yasui, Miranda M Fidler-Benaoudia, Wendy M. Leisenring, Yan Chen, Kevin C. Oeffinger, and Raoul C. Reulen
- Subjects
Cancer Research ,medicine.medical_specialty ,Lymphoma ,Childhood Cancer Survivor Study ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Risk Factors ,Internal medicine ,Survivorship curve ,Neoplasms ,medicine ,Risk of mortality ,Humans ,030212 general & internal medicine ,Survivors ,Child ,business.industry ,Cancer ,Sarcoma ,Articles ,medicine.disease ,Pediatric cancer ,Confidence interval ,United Kingdom ,United States ,Standardized mortality ratio ,Oncology ,030220 oncology & carcinogenesis ,business - Abstract
Background It is unclear whether late-effect risks among childhood cancer survivors vary internationally. We compared late mortality in the North American Childhood Cancer Survivor Study (CCSS) and British Childhood Cancer Survivor Study (BCCSS). Methods Late mortality was assessed among 49 822 5-year survivors of childhood cancer diagnosed before 15 years of age from 1970 to 1999 (CCSS, n = 31 596; BCCSS, n = 18 226) using cumulative mortality probabilities (CM%) and adjusted ratios of the standardized mortality ratio. Results The all-cause CM% at 10 years from diagnosis was statistically significantly lower in the CCSS (4.7%, 95% confidence interval [CI] = 4.5% to 5.0%) compared with the BCCSS (6.9%, 95% CI = 6.5% to 7.2%), attributable to a lower probability of death from recurrence or progression of the primary cancer, with statistically significant differences observed in survivors of leukemia, lymphoma, central nervous system tumors, and sarcoma. However, at 40 years from diagnosis, the CCSS had a greater CM% (22.3% vs 19.3%), attributable to a twofold higher risk of mortality from subsequent malignant neoplasms, cardiac and respiratory diseases, and other health-related causes. Differences increased when assessed by follow-up interval, with the CCSS faring worse as time-since-diagnosis increased. Finally, the gap in all-cause mortality widened more recently, with CCSS survivors diagnosed in 1990-1999 experiencing one-half the excess deaths observed in the BCCSS (ratios of the standardized mortality ratio = 0.5, 95% CI = 0.5 to 0.6). Conclusions Our findings suggest that US survivors may have received more intensive regimens to achieve sustainable remission and cure, but the cost of this approach was a higher risk of death from late effects. Although the clinical impact of these differences is unclear, our results provide important evidence to aid the discussion of late effects management.
- Published
- 2020
27. Cancer statistics for adolescents and young adults, 2020
- Author
-
Kimberly D. Miller, Theresa H.M. Keegan, Heather S. Hipp, Miranda M Fidler-Benaoudia, Rebecca L. Siegel, and Ahmedin Jemal
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Population ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Age Distribution ,Survivorship curve ,Neoplasms ,Epidemiology ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,Sex Distribution ,education ,education.field_of_study ,Relative survival ,business.industry ,Incidence (epidemiology) ,Incidence ,Racial Groups ,Cancer ,Hematology ,medicine.disease ,Pediatric cancer ,United States ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Demography - Abstract
Cancer statistics for adolescents and young adults (AYAs) (aged 15-39 years) are often presented in aggregate, masking important heterogeneity. The authors analyzed population-based cancer incidence and mortality for AYAs in the United States by age group (ages 15-19, 20-29, and 30-39 years), sex, and race/ethnicity. In 2020, there will be approximately 89,500 new cancer cases and 9270 cancer deaths in AYAs. Overall cancer incidence increased in all AYA age groups during the most recent decade (2007-2016), largely driven by thyroid cancer, which rose by approximately 3% annually among those aged 20 to 39 years and 4% among those aged 15 to 19 years. Incidence also increased in most age groups for several cancers linked to obesity, including kidney (3% annually across all age groups), uterine corpus (3% in the group aged 20-39 years), and colorectum (0.9%-1.5% in the group aged 20-39 years). Rates declined dramatically for melanoma in the group aged 15 to 29 years (4%-6% annually) but remained stable among those aged 30 to 39 years. Overall cancer mortality declined during 2008 through 2017 by 1% annually across age and sex groups, except for women aged 30 to 39 years, among whom rates were stable because of a flattening of declines in female breast cancer. Rates increased for cancers of the colorectum and uterine corpus in the group aged 30 to 39 years, mirroring incidence trends. Five-year relative survival in AYAs is similar across age groups for all cancers combined (range, 83%-86%) but varies widely for some cancers, such as acute lymphocytic leukemia (74% in the group aged 15-19 years vs 51% in the group aged 30-39 years) and brain tumors (77% vs 66%), reflecting differences in histologic subtype distribution and treatment. Progress in reducing cancer morbidity and mortality among AYAs could be addressed through more equitable access to health care, increasing clinical trial enrollment, expanding research, and greater alertness among clinicians and patients for early symptoms and signs of cancer. Further progress could be accelerated with increased disaggregation by age in research on surveillance, etiology, basic biology, and survivorship.
- Published
- 2020
28. Clinical Implications of Frailty in Acute Exacerbations of Interstitial Lung Disease
- Author
-
Lee M. Fidler, C. Adams, Jolene H. Fisher, Lisa Wickerson, Sunita Mathur, John Kavanagh, Wendy Darlene Reid, Lianne G. Singer, K. Chohan, Shane Shapera, Tereza Martinu, Dmitry Rozenberg, and Ewan C. Goligher
- Subjects
medicine.medical_specialty ,business.industry ,Internal medicine ,Interstitial lung disease ,Medicine ,business ,medicine.disease ,Gastroenterology - Published
- 2020
29. Emerging cancer incidence trends in Canada: The growing burden of young adult cancers
- Author
-
Miranda M Fidler-Benaoudia, Ahmedin Jemal, Emily Heer, Hyuna Sung, and Andrew Harper
- Subjects
Adult ,Male ,Cancer Research ,Canada ,Colorectal cancer ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Neoplasms ,medicine ,Humans ,030212 general & internal medicine ,Young adult ,Lung cancer ,Aged ,Cervical cancer ,Aged, 80 and over ,Cancer prevention ,business.industry ,Incidence (epidemiology) ,Incidence ,Age Factors ,Cancer ,Middle Aged ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Female ,business ,Demography - Abstract
Background Recent studies have identified increases in cancer incidence among younger adults for some cancers. This study examined incidence trends for 28 cancers in Canada by age and birth cohort from 1983 to 2012. Methods Canadian incidence data for 20 to 84 year-olds were obtained from the Cancer Incidence in Five Continents Plus database. Age-period-cohort modeling was used to estimate the average annual percentage changes (AAPCs) and incidence rate ratios (IRRs) for 10-year birth cohorts (reference cohort, 1943) for 28 cancer types. Results Incidence increased for 13 cancer sites among adults younger than 50 years (1983-2012), with the largest increase occurring for rectal cancer (AAPC20-24 , 5.62; 95% confidence interval [CI], 3.77-7.51) and colon cancer (AAPC20-24 , 4.08; 95% CI, 2.89-5.29). Compared with the 1943 birth cohort, persons born circa 1988 had approximately 5- and 2-fold greater risks of rectal cancer (IRR, 4.98; 95% CI, 2.87-8.63) and colon cancer (IRR, 2.31; 95% CI, 1.62-3.30), respectively. Incidence decreased among younger adults for 9 sites (1983-2012), with the largest decreases observed for lung cancer (AAPC25-29 ,-2.29; 95% CI, -3.57 to -0.98), cervical cancer (AAPC25-29 , -1.29; 95% CI, -1.67 to -0.90), and melanoma (AAPC25-29 , -0.61; 95% CI, -0.97 to -0.24). Decreased risks in recent birth cohorts were observed for all sites with decreasing trends in younger adults. For example, the risk of lung cancer was 60% lower in the 1988 birth cohort than the 1943 birth cohort (IRR, 0.42; 95% CI, 0.23-0.78). Conclusions Incidence among young adults is increasing for some cancers associated with obesity but decreasing for many cancers associated with infections or smoking. Although further studies are needed to replicate these findings and understand the etiology of early-onset cancers, measures to promote healthy behaviors in young adults warranted.
- Published
- 2020
30. Fear of cancer recurrence among survivors of childhood cancer
- Author
-
Kathleen Reynolds, Caitlin Forbes, Arfan R. Afzal, K. Brooke Russell, Fiona Schulte, Michaela Patton, Hayley Wroot, Lindsey Trepanier, and Miranda M. Fidler-Benaoudia
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Childhood cancer ,chemical and pharmacologic phenomena ,Experimental and Cognitive Psychology ,Cancer recurrence ,03 medical and health sciences ,0302 clinical medicine ,Cancer Survivors ,Chart review ,Survivorship curve ,Neoplasms ,Surveys and Questionnaires ,Prevalence ,Medicine ,Humans ,030212 general & internal medicine ,Child ,Depressive symptoms ,Retrospective Studies ,business.industry ,Cancer ,Fear ,Middle Aged ,medicine.disease ,humanities ,Clinic visit ,Psychiatry and Mental health ,Oncology ,Phobic Disorders ,030220 oncology & carcinogenesis ,Female ,Neoplasm Recurrence, Local ,business ,Off Treatment - Abstract
Objectives Fear of cancer recurrence (FCR) has not been widely explored in survivors of childhood cancer. Yet, childhood survivors are at risk of experiencing late effects and may be especially vulnerable. The aims of the current study were to conduct a retrospective chart review to determine the prevalence and persistence of FCR among survivors of childhood cancer and to examine factors that may be related to FCR. Methods Survivors of childhood cancer (n = 228, mean attained age = 14.5 years [range = 4.7-21 years]; mean diagnosis age = 4.4 years [range = 0-16.5 years]; mean time off treatment = 8.7 years [range = 2.8-19.3 years]) seen in a Long-Term Survivor Clinic (LTSC) completed questionnaires at each clinic visit detailing their current health. FCR was measured with a single item. Data from questionnaires from 2011 to 2018 were analyzed retrospectively. Descriptive statistics and a random effects model were used to address study aims. Results FCR was reported in 43% (n = 98) of survivors at least once across all clinic visits. Among survivors reporting FCR at least once, 66% were diagnosed with cancer under the age of 5, and 64% were 13 years or older at their most recent follow-up. Twenty-one percent of survivors (n = 48/224) reported FCR during at least 50% of their visits. Survivors with a higher number of depressive symptoms were more likely to report FCR (OR = 1.66, P = .03). Conclusions FCR is prevalent among survivors of childhood cancer and is related to other health concerns. Research is needed to understand who is at risk and how to.
- Published
- 2019
31. Antacid Therapy in Idiopathic Pulmonary Fibrosis
- Author
-
Lee M. Fidler and Kerri A. Johannson
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pendulum ,Critical Care and Intensive Care Medicine ,medicine.disease ,Gastroenterology ,Idiopathic pulmonary fibrosis ,Antacid therapy ,Internal medicine ,medicine ,Cardiology and Cardiovascular Medicine ,business - Published
- 2021
32. The global cancer burden and human development: A review
- Author
-
Miranda M. Fidler, Isabelle Soerjomataram, and Freddie Bray
- Subjects
0301 basic medicine ,business.industry ,Developed Countries ,Public Health, Environmental and Occupational Health ,Health Status Disparities ,General Medicine ,Global Health ,Human development (humanity) ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Neoplasms ,030220 oncology & carcinogenesis ,Environmental health ,Cancer burden ,Humans ,Medicine ,business ,Developing Countries ,Socioeconomic status - Abstract
Aims: This review examines the links between human development and cancer overall and for specific types of cancer, as well as cancer-related risk-factors and outcomes, such as disability and life expectancy. Methods: To assess human development, the Human Development Index was utilized continuously and according to four levels (low, medium, high, very high), where the low and very high categories include the least and most developed countries, respectively. All studies that assessed aspects of the global cancer burden using this measure were reviewed. Results: Although the present cancer incidence burden is greater in higher Human Development Index countries, a greater proportion of the global mortality burden is observed in less developed countries, with a higher mean fatality rate in the latter countries. Further, the future cancer burden is expected to disproportionally affect less developed regions; in particular, it has been estimated that low and medium Human Development Index countries will experience a 100% and 81% increase in cancer incidence from 2008 to 2030, respectively. Disparities were also observed in risk factors and average health outcomes, such as a greater number of years of life lost prematurely and fewer cancer-related gains in life expectancy observed in lower versus higher Human Development Index settings. Conclusions: From a global perspective, there remain clear disparities in the cancer burden according to national Human Development Index scores. International efforts are needed to aid countries in social and economic transition in order to efficiently plan, implement and evaluate cancer control initiatives as a means to reduce the widening gap in cancer occurrence and survival worldwide.
- Published
- 2017
33. Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup
- Author
-
Leontien C.M. Kremer, Daniela Alessi, Thomas Wiebe, Roderick Skinner, Vera Morsellino, Gisela Michel, Melanie Kaiser, Finn Wesenberg, Rodrigue S. Allodji, Claudia E. Kuehni, David L. Winter, Päivi M. Lähteenmäki, Jeanette Falck Winther, Momcilo Jankovic, Neige Journy, Eva-Maria Hau, Zsuzsanna Jakab, Andrea Bautz, Michael M. Hawkins, Jop C Teepen, Imene Mansouri, Joyeeta Guha, Florent de Vathaire, Giao Vu-Bezin, Edit Bardi, Carlotta Sacerdote, Lorna Zadravec Zaletel, Damien Llanas, Peter Kaatsch, Lars Hjorth, Cécile M. Ronckers, Carole Rubino, Nadia Haddy, Monica Muraca, Julianne Byrne, Thorgerdur Gudmundsdottir, Ibrahima Diallo, Stanislaw Garwicz, Monica Terenziani, Hilde Øfstaas, Helena M. Linge, Chloe J Bright, Brice Fresneau, Miranda M Fidler-Benaoudia, Elizabeth Lieke A.M. Feijen, Cristina Veres, Riccardo Haupt, Raoul C. Reulen, Desiree Grabow, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Graduate School, CCA - Cancer Treatment and Quality of Life, ARD - Amsterdam Reproduction and Development, and Paediatric Oncology
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Pediatrics ,Myeloid ,[SDV]Life Sciences [q-bio] ,Childhood cancer survivors ,Cohort Studies ,0302 clinical medicine ,Cancer Survivors ,Risk Factors ,Registries ,Child ,Myeloid leukaemias ,education.field_of_study ,Leukemia ,Incidence ,Incidence (epidemiology) ,Neoplasms, Second Primary ,Prognosis ,3. Good health ,Europe ,medicine.anatomical_structure ,Second cancers ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Cohort ,Female ,Cohort study ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,Subsequent primary leukaemia ,Risk Assessment ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,education ,business.industry ,Infant, Newborn ,Infant ,Cancer ,medicine.disease ,Confidence interval ,030104 developmental biology ,Relative risk ,business ,Lymphoid leukaemias ,Follow-Up Studies - Abstract
Background Survivors of childhood cancers are at risk of developing subsequent primary leukaemias (SPLs), but the long-term risks beyond 20 years of treatment are still unclear. We investigated the risk of SPLs in five-year childhood cancer survivors using a large-scale pan-European (PanCareSurFup) cohort and evaluated variations in the risk by cancer and demographic factors. Methods This largest-ever assembled cohort comprises 69,460 five-year childhood cancer survivors from 12 European countries. Standardised incidence ratios (SIRs) and absolute excess risks (AERs) were calculated. Results One hundred fifteen survivors developed an SPL including 86 myeloid leukaemias (subsequent primary myeloid leukaemias [SPMLs]), 17 lymphoid leukaemias and 12 other types of leukaemias; of these SPLs, 31 (27%) occurred beyond 20 years from the first childhood cancer diagnosis. Compared with the general population, childhood cancer survivors had a fourfold increased risk (SIR = 3.7, 95% confidence interval [CI]: 3.1 to 4.5) of developing leukaemia, and eight leukaemias per 100,000 person-years (AER = 7.5, 95% CI: 6.0 to 9.2) occurred in excess of that expected. The risks remained significantly elevated beyond 20 years from the first primary malignancy (SIR = 2.4, 95% CI: 1.6 to 3.4). Overall, the risk ratio for SPML (SIR = 5.8, 95% CI: 4.6 to 7.1) was higher than that for other SPLs. Conclusions We demonstrate that beyond 20 years after childhood cancer diagnosis, survivors experience an increased risk for SPLs compared with that expected from the general population. Our findings highlight the need for awareness by survivors and their healthcare providers for potential risk related to SPL.
- Published
- 2019
34. Childhood Leukemia, Late Effects, and a Person-centric Model of Follow-up
- Author
-
Kevin C. Oeffinger and Miranda M Fidler-Benaoudia
- Subjects
Cancer Research ,Pediatrics ,medicine.medical_specialty ,Leukemia ,Childhood leukemia ,business.industry ,Articles ,Scandinavian and Nordic Countries ,medicine.disease ,Hospitalization ,Oncology ,hemic and lymphatic diseases ,Medicine ,population characteristics ,Humans ,Survivors ,business ,Child ,Follow-Up Studies - Abstract
BACKGROUND: Adverse effects from childhood leukemia treatment may persist or present years after cure from cancer. We provide a comprehensive evaluation of subsequent hospitalization in five-year survivors of childhood acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). METHODS: In the Adult Life after Childhood Cancer in Scandinavia Study, we identified 4003 five-year survivors diagnosed with childhood leukemia 1970–2008 in Denmark, Sweden, Iceland, and Finland. Survivors and 129 828 population comparisons were followed for first-time nonpsychiatric hospitalizations for 120 disease categories in the hospital registries. Standardized hospitalization rate ratios and absolute excess rates were calculated. All statistical tests were two-sided. RESULTS: Survivors of ALL (n = 3391), AML (n = 389), and CML (n = 92) had an increased overall hospitalization rate compared with population comparisons. The rate ratio for any hospitalization was 1.95 (95% confidence interval [CI] = 1.83 to 2.07) in ALL, 3.09 (95% CI = 2.53 to 3.65) in AML, and 4.51 (95% CI = 3.03 to 6.00) in CML survivors and remained increased even 20 years from leukemia diagnosis. Corresponding absolute excess rates per 1000 person-years were 28.48 (95% CI = 24.96 to 32.00), 62.75 (95% CI = 46.00 to 79.50), and 105.31 (95% CI = 60.90 to 149.72). CONCLUSION: Leukemia survivors have an increased rate of hospitalization for medical conditions. We provide novel insight into the relative and absolute rate of hospitalization for 120 disease categories in survivors of ALL, AML, and CML, which are likely to be informative for both survivors and healthcare providers.
- Published
- 2019
35. Emerging Cancer Incidence Trends in Canada: A Population-Based Study of the Growing Burden of Young Adult Cancers
- Author
-
Ahmedin Jemal, Emily Heer, Miranda M Fidler-Benaoudia, Andrew Harper, and Hyuna Sung
- Subjects
business.industry ,Colorectal cancer ,Incidence (epidemiology) ,medicine.medical_treatment ,Cancer ,medicine.disease ,Obesity ,Cohort ,Medicine ,Smoking cessation ,Young adult ,business ,Lung cancer ,Demography - Abstract
Background: Recent studies have identified significant increases in cancer incidence among younger adults for some cancers. We examined incidence trends of 27 cancer sites in Canada by age and birth cohort between 1983 and 2012. Methods: Canadian incidence data for 20-84 year-olds was obtained from the Cancer in Five Continents plus database. The average annual percentage change (AAPC) was calculated, and age-period-cohort modeling was used to estimate incidence rate ratios for 10-year birth cohorts. Results: Incidence significantly increased in 12 cancer sites among adults
- Published
- 2019
36. Plantar Fasciitis and Tarsal Tunnel
- Author
-
Gregory C. Berlet and Corey M. Fidler
- Subjects
medicine.medical_specialty ,Heel ,business.industry ,Enthesopathy ,Plantar fasciitis ,Orthotics ,Tarsal tunnel syndrome ,Lateral plantar nerve ,medicine.disease ,Surgery ,body regions ,medicine.anatomical_structure ,medicine ,Etiology ,Tarsal tunnel ,medicine.symptom ,business - Abstract
Plantar fasciitis is one of the most common foot conditions affecting individuals both with a high level of activity and those with a high level of inactivity. While the diagnosis is frequently clear, the etiology has remained controversial. Up to 90–96% of plantar fasciitis cases resolve with nonoperative management including nonsteroidal anti-inflammatory drugs (NSAIDs), stretching, orthotics, oral/injectable steroid, physical therapy modalities, rest, night splints, and immobilization. When patients who present with the characteristic enthesopathy of plantar fasciitis develop neurogenic symptoms, other etiologies need to be investigated. A commonly overlooked source of inferomedial heel pain recalcitrant to nonoperative management is chronic plantar fasciitis associated with entrapment of the lateral plantar nerve and its first branch.
- Published
- 2019
37. Tibialis Anterior Tendon Ruptures
- Author
-
Corey M. Fidler and Patrick E. Bull
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,Foot drop ,business.industry ,Inflammatory arthritis ,musculoskeletal system ,medicine.disease ,Tendon ,Gout ,Surgery ,Blunt ,medicine.anatomical_structure ,medicine ,Eccentric ,Ankle ,Tendinopathy ,medicine.symptom ,business - Abstract
Ruptures of the tibialis anterior tendon are uncommon but will typically present after an acute injury or as either an acute or chronic foot drop. In the setting of an acute injury, the injury mechanism is typically blunt tendon trauma or laceration. Acute ruptures of a healthy tendon are rare. Atraumatic ruptures tend to occur in older individuals with underlying chronic tendinopathy. Those patients with diabetes mellitus, inflammatory arthropathy, or gout, or who are undergoing treatment with corticosteroids, are at higher risk for spontaneous ruptures. A minor traumatic event may involve an eccentric load applied to a plantar-flexed ankle.
- Published
- 2019
38. Global Burden and Trends in Pre- and Post-Menopausal Breast Cancer
- Author
-
Emily Heer, Miranda M Fidler-Benaoudia, Andrew Harper, Noah Escandor, Valerie McCormack, and Hyuna Sung
- Subjects
Breast cancer ,business.industry ,Incidence (epidemiology) ,Mortality rate ,medicine ,Breastfeeding ,Developing country ,Human Development Index ,medicine.disease ,business ,Developed country ,Obesity ,Demography - Abstract
Background: Breast cancer has distinct etiologies, prognoses, and patient impact at pre- and post-menopausal ages. We sought to assess the global burden and trends in breast cancer by menopausal status. Methods: Menopausal status was defined using age as a proxy, where breast cancer cases/deaths at >50 years were considered as post-menopausal. Age-standardized breast cancer incidence and mortality rates in 2018 were calculated using GLOBOCAN data. Incidence trends for 1998-2012 were assessed in 44 populations from 41 countries using CI5plus data by calculating the annual average percent change. Findings: Approximately 645,000 pre-menopausal and 1.4 million post-menopausal breast cancer cases were diagnosed in 2018, with approximately 130,000 and 490,000 deaths occurring in each menopausal group, respectively. Proportionally, Low Human Development Index (HDI) countries faced a greater burden of pre-menopausal breast cancer for both incidence and mortality compared to more developed countries. Very High HDI countries had the highest pre- and post-menopausal breast cancer incidence rates (30·6 and 253·6 per 100,000 respectively), while Low and Medium HDI countries had the highest pre-menopausal and post-menopausal mortality rates respectively (8·5 and 53·3 per 100,000 respectively). When examining incidence trends, we observed significantly increasing rates of pre-menopausal breast cancer in 20/44 populations, and significantly increasing rates of post-menopausal breast cancer in 24/44 populations. The increases exclusively at pre-menopausal ages largely occurred in the most developed countries, while the increasing post-menopausal breast cancer burden was most notable in countries under transition. Interpretation: We provide evidence of a rising burden of both pre- and post-menopausal breast cancer worldwide, and wide inequities in breast cancer care. Although early diagnosis and access to treatment remain crucial in developing countries, primary prevention efforts seeking to decrease obesity and alcohol consumption, and increase physical activity and breastfeeding, are warranted in all world regions to curb the future breast cancer burden. Funding Statement: This study was undertaken without any funding. Declaration of Interests: All authors declare no conflicts of interests. Ethics Approval Statement: Not required.
- Published
- 2019
39. A global view on cancer incidence and national levels of the human development index
- Author
-
Freddie Bray, Miranda M. Fidler, and Isabelle Soerjomataram
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Melanoma ,Thyroid ,medicine.disease ,Human development (humanity) ,Lymphoma ,03 medical and health sciences ,Leukemia ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Internal medicine ,Immunology ,medicine ,030212 general & internal medicine ,Sarcoma ,business ,Multiple myeloma - Abstract
Socioeconomic factors are associated with cancer incidence through complex and variable pathways. We assessed cancer incidence for all cancers combined and 27 major types according to national human development levels. Using GLOBOCAN data for 184 countries, age-standardized incidence rates (ASRs) were assessed by four levels (low, medium, high, very high) of the Human Development Index (HDI), a composite index of life expectancy, education, and gross national income. A strong positive relationship between overall cancer incidence and HDI level was observed. When comparing the ASR in very high HDI regions with that in low HDI regions, we observed a positive association ranging from 2 to 14 and 2 to 11 times higher in males and females, respectively, depending on the cancer type. Positive dose–response relationships between the ASR and HDI level were observed in both sexes for the following cancer types: lung, pancreas, leukemia, gallbladder, colorectum, brain/nervous system, kidney, multiple myeloma, and thyroid. Positive associations were also observed for testicular, bladder, lip/oral cavity, and other pharyngeal cancers, Hodgkin lymphoma, and melanoma of the skin in males, and corpus uteri, breast, and ovarian cancers and non-Hodgkin lymphoma in females. A negative dose–response relationship was observed for cervical and other pharyngeal cancers and Kaposi sarcoma in females. Although the relationship between incidence and the HDI remained when assessed at the country-specific level, variations in risk within HDI levels were also observed. We highlight positive and negative associations between incidence and human development for most cancers, which will aid the planning of cancer control priorities among countries undergoing human development transitions.
- Published
- 2016
40. Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study
- Author
-
Helen C. Jenkinson, Elaine Sugden, Joyeeta Guha, Kathryn Pritchard-Jones, Julie Kelly, David L. Winter, Miranda M. Fidler, Michael M. Hawkins, Emma R Lancashire, Gill Levitt, Raoul C. Reulen, Clare Frobisher, and Kwok Wong
- Subjects
Adult ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Adverse outcomes ,Health Status ,MEDLINE ,Childhood Cancer Survivor Study ,Wilms Tumor ,03 medical and health sciences ,Health services ,0302 clinical medicine ,medicine ,Humans ,Survivors ,030212 general & internal medicine ,Educational achievement ,Child ,Digestive cancer ,Aged ,business.industry ,Infant, Newborn ,Infant ,Wilms' tumor ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Oncology ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,Risk of death ,Neoplasm Recurrence, Local ,business - Abstract
Purpose Survivors of Wilms tumor (WT) are at risk for adverse health and social outcomes but risks beyond 30 years from diagnosis remain uncertain. We investigated the risks of adverse outcomes among 5-year survivors of WT, in particular, those between 30 and 50 years from diagnosis. Patients and Methods The British Childhood Cancer Survivor Study includes 1,441 5-year survivors of WT. We investigated cause-specific mortality, risk of subsequent primary neoplasms (SPNs), and, for those who completed a questionnaire, the extent of smoking and drinking, educational achievement, health status, and health service use compared with the general population. Results Cumulative risk of death from all causes, excluding recurrence, increased substantially from 5.4% to 22.7% at 30 years and 50 years, respectively, after WT diagnosis—75% of excess deaths beyond 30 years from diagnosis were attributable to SPNs (50%) and cardiac diseases (25%). Digestive cancer, most frequently bowel, accounted for 41% of excess cancers beyond 30 years. Conclusion Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases. Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients with WT who are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of this group should focus on SPNs, in particular, bowel and breast cancers, and cardiac conditions.
- Published
- 2016
41. Beaming in Charcot Arthropathy—Intramedullary Fixation for Complicated Reconstructions: A Cadaveric Study
- Author
-
Benjamin C. Watson, Christopher W. Reb, Corey M. Fidler, and Christopher F. Hyer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Arthrodesis ,medicine.medical_treatment ,Bone Screws ,law.invention ,Intramedullary rod ,03 medical and health sciences ,Fixation (surgical) ,0302 clinical medicine ,law ,Arthropathy ,Cadaver ,medicine ,Humans ,Orthopedics and Sports Medicine ,Metatarsal Bones ,Aged ,Aged, 80 and over ,030222 orthopedics ,business.industry ,Soft tissue ,030229 sport sciences ,Anatomy ,Middle Aged ,medicine.disease ,Fracture Fixation, Intramedullary ,Surgery ,Diaphysis ,medicine.anatomical_structure ,Calipers ,Female ,Diaphyses ,Arthropathy, Neurogenic ,Cadaveric spasm ,business - Abstract
In the modern treatment of Charcot neuroarthropathy, beam screw fixation is an alternative to plate and screw fixation. Exposure is minimized for implantation, and this technique supports the longitudinal columns of the foot as a rigid load-sharing construct. A published data review identified a paucity of data regarding metatarsal intramedullary canal morphology relevant to beam screw fixation. The purpose of the present study was to describe metatarsal diaphyseal morphology qualitatively and quantitatively in an effort to provide data that can be used by surgeons when selecting axially based intramedullary fixation. Twenty fresh-frozen cadaveric below-the-knee specimens were obtained. The metatarsals were exposed, cleaned of soft tissue, and axially transected at the point of the narrowest external diameter. Next, a digital caliper was used to measure the size and shape of the diaphysis of the first through fourth metatarsals. The diaphyseal canal shape was categorized as round, oval, triangular, or pear. The widest distance between the endosteal cortical surfaces was measured. Triangular endosteal canals were only found in the first metatarsal, and the remainder of the metatarsal canals were largely round or oval. These data help to approximate the size of fixation needed to achieve maximal screw-endosteal purchase.
- Published
- 2017
42. Impact of universal health care and screening on incidence and survival of Thai women with cervical cancer: A population-based study of the Chiang Mai Province
- Author
-
Donsuk Pongnikorn, Narate Waisri, Aude Bardot, Isabelle Soerjomataram, Patumrat Sripan, Miranda M Fidler-Benaoudia, Imjai Chitapanarux, Puttachart Maneesai, Adalberto Miranda-Filho, Ekkasit Tharavichitkul, and Chirapong Hanpragopsuk
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Chiang mai ,Adolescent ,Epidemiology ,Population ,Uterine Cervical Neoplasms ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Humans ,Medicine ,030212 general & internal medicine ,education ,Early Detection of Cancer ,Aged ,Aged, 80 and over ,Cervical cancer ,education.field_of_study ,Relative survival ,business.industry ,Obstetrics ,Incidence ,Incidence (epidemiology) ,Middle Aged ,Thailand ,medicine.disease ,Survival Rate ,Population based study ,Oncology ,030220 oncology & carcinogenesis ,Universal Health Care ,Universal health care ,Female ,Thai women ,business - Abstract
Universal Health Coverage (UHC) was implemented in Thailand in 2002. This study aims to compare cervical cancer incidence and survival before and after the implementation of UHC, including the national screening program, in the Chiang Mai population in Northern Thailand. Data of women diagnosed with in situ or malignant cervical cancer in Chiang Mai during 1998-2012 were used in our analysis. Annual age-standardized incidence rates (ASR) and age-adjusted relative survival (RS) were estimated for the following three diagnosis periods: period I: 1998-2002 (before UHC), period II: 2003-2007 (UHC implementation) and period III: 2008-2012 (after UHC). The ASR peaked in 2001 at 38 per 100,000, and then subsequently declined to 23 per 100,000 in 2012. The proportion of in situ and localized tumors increased in all age groups, while regional tumors declined. In all women (aged 15-89) with malignant cervical cancer or in situ, the 5-year RS in Period I, Period II and Period III was 73%, 74% and 77%, respectively; when only malignant cases were considered, the RS was 63%, 61% and 62%, respectively. In the screening target women (aged 30-59) with malignant or in situ tumors, the 5-year RS was 84%, 88% and 90%, respectively, in the three periods, while the RS was 71%, 74% and 75%, respectively, in only those with malignant cancers. The introduction of UHC including national cervical cancer screening program has likely reduced the magnitude and severity of cervical cancer and improved the survival of cervical cancer in the screening target age group.
- Published
- 2019
43. Global Cancer Inequalities
- Author
-
Miranda M. Fidler and Freddie Bray
- Subjects
Cancer Research ,Economic growth ,Inequality ,media_common.quotation_subject ,Standard of living ,DALYs ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Political science ,cancer ,Social inequality ,030212 general & internal medicine ,Human Development Index ,media_common ,social inequalities ,Composite indicator ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,global ,mortality ,Gross national income ,Oncology ,030220 oncology & carcinogenesis ,Perspective ,Life expectancy ,incidence - Abstract
Social inequalities in cancer are increasingly relevant to research, implementation science, and policy. In this brief perspective we provide an overview of global cancer inequalities by assessing different outcomes according to the Human Development Index (HDI) ; the HDI is a United Nations Development Programme composite indicator including the following measures: (i) access to education (based on mean and expected years of schooling), (ii) a long and healthy life (based on life expectancy), and (iii) a decent standard of living (based on gross national income per capita). We additionally touch upon the importance of prevention, access to oncological services, and the need to monitor progress in reducing and avoiding inequalities at subnational, national, world region, and global levels.
- Published
- 2018
44. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial
- Author
-
Scott E Kasner, Balakumar Swaminathan, Pablo Lavados, Mukul Sharma, Keith Muir, Roland Veltkamp, Sebastian F Ameriso, Matthias Endres, Helmi Lutsep, Steven R Messé, J David Spence, Krassen Nedeltechev, Kanjana Perera, Gustavo Santo, Veronica Olavarria, Arne Lindgren, Shrikant Bangdiwala, Ashkan Shoamanesh, Scott D Berkowitz, Hardi Mundl, Stuart J Connolly, Robert G Hart, N Abdelhamid, D Abdul Rahman, M Abdul-Saheb, P Abreu, M Abroskina, F Abu Ahmad, S Accassat, M Acciaresi, A Adami, N Ahmad, F Ahmed, M Alberto Hawkes, F Alemseged, A Ali, R Altavilla, L Alwis, P Amarenco, S Amaro, LE Amaya Sanchez, A Amelia Pinto, SF Ameriso, H Amin, T Amino, AK Amjad, E Anagnostou, G Andersen, C Anderson, DC Anderson, M Andrea Falco, F Andres Mackinnon, D Andreu, M Androulakis, M Angel Gamero, G Angel Saredo, R Angeles Diaz, M Angels Font, S Anticoli, A Arauz, AA Arauz Gongora, P Araya, JF Arenillas Lara, S Arias Rivas, M Arnold, S Augustin, W Avelar, E Azevedo, V Babikian, A Bacellar, K Badalyan, HJ Bae, EM Baez Martinez, H Bagelmann, P Bailey, Z Bak, M Baker, A Balazs, D Baldaranov, I Balogun, T Balueva, Z Bankuti, M Bar, A Baranowska, J Bardutzky, S Barker Trejo, J Barlinn, F Baronnet, C Barroso, M Barteys, T Bartolottiova, A Barulin, M Bas, S Bashir, V Basile, R Bathe-Peters, R Bathula, C Batista, H Batur Caglayan, P Baumgartner, R Bazan, O Bazhenova, M Beaudry, J Beer, Y Behnam, C Beilei, A Beinlich, Y Bejot, A Belkin, OR Benavente, A Benjamin, V Berardi, D Bereczki, SD Berkowitz, J Berlingieri, W Berrios, J Berrouschot, M Bhandari, M Bhargavah, H Bicker, T Bicsak, M Bilik, D Bindila, J Birchenall, L Birnbaum, T Black, D Blacker, D Blacquiere, C Blanc-Labarre, C Blank, B Blazejewska-Hyzorek, S Bloch, E Bodiguel, E Bogdanov, L Boos, L Borcsik, N Bornstein, S Bouly, G Braga, I Bragado, MC Bravi, C Brokalaki, W Brola, R Brouns, D Bruce, J Brzoska-Mizgalska, B Buck, M Buksinska-Lisik, J Burke, M Burn, G Bustamante, L Cabrejo, K Cai, S Cajaraville, M Calejo, D Calvet, J Campillo, E Campos Costa, P Camps, H Can Alaydin, E Candeloro, C Canepa, CG Cantu Brito, M Cappellari, C Carcel, P Cardona Portela, F Cardoso, M Carek, M Carletti, J Carlos Portilla, P Caruso, I Casado-Naranjo, P Castellini, D Castro, F Castro Meira, A Cavallini, N Cayuela Caudevilla, S Cenciarelli, C Cereda, P Cerrone, A Chakrabarti, P Chaloulos-Iakovidis, A Chamorro, D Chandrasena, DI Chang, C Che, J Chembala, J Chen, Z Chen, T Chen, H Chen, X Chen, G Chen, L Chen, S Chen, B Cheripelli, M Chin, E Chiquete Anaya, M Chorazy, H Christensen, T Christensen, L Christian, F Chu, CS Chung, W Clark, R Clarke, S Claverie, E Clemente Agostoni, B Clissold, J Coelho, D Cohen, S Colakoglu, D Collas, R Condurso, SJ Connolly, D Consoli, C Constantin, AB Constantino Silva, L Contardo, A Corlobe, M Correia, C Correia, E Cortijo Garcia, B Coull, S Coutts, S Coveney, P Cras, R Crols, S Crozier, A Csanyi, L Csiba, K Csontos, R Csuha, L Cui, L Cunha, S Curtze, M Czerska, A Czlonkowska, M Czurko, M Czuryszkiewicz, M Dagnino, C Dai, A Daineko, G Dalek, D Damgaard, A Danese, K Dani, V Danku, W Dario Toledo, A Dávalos, A De Havenon, J De Keyser, N De Klippel, J De La Torre, A De Pauw, A De Smedt, R De Torres, MM De Vries Basson, J Dearborn, R Deganutto, M Degeorgia, I Deguchi, A Del Giudice, C Delcourt, R Delgado-Mederos, G Della Marca, B Delpont, S Deltour, DL Demets, M Dennis, J Desai, J Devine, I Dhollander, MT Di Mascio, M Diaconu, F Diaz Otero, J Dietzel, E Diez-Tejedor, N Ding, J Ding, M Diomedi, P Dioszeghy, M Distefano, V Domigo, E Dorodnicov, D Dossi, F Doubal, I Druzenko, P Du, J Du, T Duman, Y Duodu, D Dutta, L Dylewicz, J Eckstein, E Ehrensperger, S Ehrlich, G Einer Allende, B Elena Halac, S Elyas, M Endres, JM Engelbrecht, S Engelter, M Epinat, F Eren, M Esbjornsson, B Escribano, I Escudero, B Esisi, B Essa, M Esterbauer, N Evans, D Eveson, S Fabio, L Fang, S Fanta, M Fares, M Fatar, K Faust, A Favate, F Fazekas, M Federica Denaro, A Fedin, P Felipe Amaya, J Feng, K Ferencova, M Fernanda Gilli, MD Fernandez, PN Fernandez Pirrone, J Fernandez Vera, J Ferrari, A Ferreira, G Ferreira Junior, M Fidler, D Field, T Field, C Figueroa, J Fiksa, A Filipov, A Firstenfeld, L Fisch, U Fischer, M Fisselier, U Fiszer, F Fluri, G Fortea, K Fotherby, A Fraczek, E France, G Freitas, S Frey, M Frick, A Friedman, M Friedrich, G Frisullo, W Fryze, B Fuentes Gimeno, H Fujigasaki, K Fukuyama, A Furlan, G Furlanis, J Furnace, M Gabriel, E Gabriel Reich, RJ Gagliardi, F Galati, E Galli Giqueauk, A Gallina, E Gallinella, J Gallo, S Gangadharan, Y Gao, R Garcia Lopez, A Garcia Pastor, SM Garcia Sanchez, M Garnauf, P Garnier, D Gasecki, K Gasic, K Gasiorek, S Gasser, M Gaugg, M Gebreyohanns, K Gebura, J Geng, M Geniz Clavijo, K Georg Haeusler, R Geran, M Geremek, Z Gerocs, D Ghia, D Giannandrea, F Giatsidis, JA Gien Lopez, A Gil Nunez, L Gimenez, E Giralt, A Glabinski, D Gladstone, M Gliem, M Gluszkiewicz, R Goddeau, E Gogoleva, M Gokce, D Goldemund, K Golikov, A Gomes Neto, M Gomez Schneider, M Gomez-Choco, M Gomis, JF Gongora-Rivera, Y Gonysheva, L Gonzalez, ME Gonzalez Toledo, M Gottschal, I Gozdzik, S Grabowski, S Graf, D Green, D Greer, T Gregorio, S Greisenegger, I Greshnova, M Griebe, M Grzesik, J Guan, S Guarda, A Gueguen, C Guidoux, P Guillermo Povedano, B Guillon, V Guiraudg, G Gunathilagan, N Guryanova, V Gusev, G Gustavo Persi, R Gutiérrez, P Guyler, N Gyuker, V Hachinski, A Hajas, H Hallevi, G Hankey, GJ Hankey, L Hanouskova, L Hao, K Haraguchi, Y Haralur Sreekantaiah, S Haratz, D Hargroves, K Harkness, P Harmel, M Harrasser, RG Hart, M Harvey, R Hasan, Y Hasegawa, A Hassan, M Hattori, A Hatzitolios, M Hauk, T Hayashi, H Hayhoe, VS Hedna, M Heine, V Held, S Hellwig, J Henkner, N Henninger, S Hermans, J Hernandez, D Herrero, M Hervieu-Begue, R Herzig, L Hicken, M Hieber, M Hill, M Hirose, MC Hobeanu, B Hobson, M Hochstetter, J Hoe Heo, M Hoffmann, C Holmstedt, P Hon, KS Hong, Y Honma, A Horev, G Horgan, L Horvath, M Horvath, C Hoyer, D Huang, H Huang, B Huber, J Huhtakangas, M Hussain, S Igarashi, AM Iglesias Mohedano, J Ignacio Tembl, M Impellizzeri, Y Inanc, P Ioli, A Irina Aniculaesei, K Ishida, R Itabashi, H Iversen, A Jagolino, K Jakab, S Jander, H Janka, J Jankovych, J Jansen, L Jasek, M Javier Alet, L Javor, X Jin, P Jing, B Joachim, M Joan Macleod, M Johnson, J Jose Martin, C Joyner, K Judit Szabo, A Jun-Oconnell, R Jura, B Kaczorowska, J Kadlcikova, T Kahles, N Kakaletsis, I Kakuk, K Kalinowska, K Kaminska, C Kaneko, I Kanellos, P Kapeller, K Kapica-Topczewska, O Karasz, M Karlinski, JE Karlsson, K Kasa, E Kashaeva, SE Kasner, M Kaste, J Kasza, A Katalin Iljicsov, M Katsurayama, S Kaur, M Kawanishi, S Kaygorodtseva, K Ke, A Kei, J Keilitz, J Kellner, P Kelly, S Kelly, D Kemlink, M Kerekgyarto, I Keskinarkaus, D Khairutdinova, A Khanna, A Khaw, M Kholopov, C Khoumri, S Kirpicheva, H Kirshner, K Kitagawa, S Kittner, R Kivioja, F Klein, D Kleindorfer, T Kleinig, P Klivenyi, S Knecht, Y Kobayashi, A Kobayashi, M Koch, L Koehler, M Koivu, V Kolianov, I Koltsov, T Kondo, I Konkov, S Kopecky, E Korompoki, J Korpela, K Kosarz-Lanczek, A Koutroubi, K Kovacs, T Kovacs, H Kovacs, K Kowalczyk, M Kowalska, D Krajickova, M Kral, C Krarup Hansen, J Kraska, S Krebs, V Krejci, C Kremer, R Kreuzpointer, M Krzyzanowska, D Kucken, A Kulakowska, J Kunzmann, N Kurenkova, A Kuris, I Kurkowska-Jastrzebska, N Kurtenkova, O Kurushina, G Kusnick, M Kustova, T Kuwashiro, J Kwan Cha, A Lago, M Lagutenko, B Lajos, J Lambeck, C Lamy, A Landolfi, S Lanfranconi, W Lang, LB Lara Lezama, B Lara Rodriguez, T Largo, A Lasek-Bal, L Latte, V Lauer, P Lavados, R Le Bouc, R Leal Cantu, H Lechner, K Lecouturier, S Leder, J Lee, BC Lee, A Leger, E Leira, I Leisse, R Leker, G Lembo, L Lenskaya, J Leyden, G Li, M Li, S Li, J Li, G Liamis, H Liang, Z Liang, N Ligot, H Lin, R Lindert, A Lindgren, M Linna, T Litwin, K Liu, X Liu, L Llull, B Lohninger, M Longoni, C Loomis, D Lopes, M Lopez Fernandez, N Lopez Garza, A Lord, S Louw, R Lovasz, T Lowenkopf, Z Lu, SC Lubke-Detring, R Luder, S Lujan, B Luo, L Lupinogina, G Luschin, H Lutsep, A Lvova, J Ly, G.M. Grosse, H Ma, C Ma, M Machado, C Machado, S Macher, J Machetanz, F Macian-Montoro, E Mackey, A Mackey, G Maclean, J Maestre-Moreno, A Magadan, T Magyar, A Mahagney, A Majid, A Majjhoo, K Makaritsis, J Mandzia, M Mangas Guijarro, D Mangion, E Manios, S Mann, L Manning, C Manno, J Manuel Garcia, V Maqueda, M Mar Castellanos, M Mar Freijo, C Marando, S Marcela Lepera, J Marcos Couto, G Maria Bruera, L Maria Greco, A Maria Lorenzo, S Maria Obmann, A Maria Roa, C Marini, I Marinkovic, G Mario Sumay, C Mario Torres, M Marko, S Markova, H Markus, R Marsh, E Marsili, M Marta Esnaola, J Marta Moreno, J Marti-Fabregas, S Martina Angelocola, P Martínez Sánchez, N Martinez-Majander, S Martins, O Marzelik, S Mastrocola, G Matamala, A Matoltsy, B Matosevic, S Matsumoto, A Maud, G Mauri Cabdevila, Z May, Y Mayasi, A Mayr, T Mazzoli, K Mcarthur, L Mccullough, CE Medina Pech, F Medlin, M Mehdiratta, S Mehta, D Mehta, B Mehta, M Melis, E Melnikova, B Mendez, T Mendonca, JJ Mengual Chirifie, N Menon, A Mensch, E Meseguer, S Messe, K Metcalf, N Meyer, F Michas, N Micheletti, R Mikulik, H Milionis, B Miller, T Milling, C Minelli, J Minhas, M Minns, D Mircea, S Mishra, A Mismas, A Mistri, N Mitrovic, H Miyake, B Modrau, A Moey, C Molina, J Molina, A Molis, J Moller, S Molnar, F Moniche, C Monosi, V Monzani, M Moonis, R Morais, L Morales, A Morales, D Morar-Precup, F Moreton, C Moro, E Morozova, M Morton, T Morvan, E Morvan, T Motko, A Mowla, E Mozhejko, G Muddegowda, O Mudhar, T Mueller, C Muhl, KW Muir, H Mundl, S Munoz, C Murphy, S Murphy, A Murtuzova, T Musuka, J Mutzenbach, M Myint, W Mysliwy, M Naccarato, G Naeije, Y Nagakane, I Natarajan, D Navaratnam, A Nave, B Nazliel, K Nedeltchev, J Nel, H Nell, R Nemeth, L Nemeth, O Neto, K Ng, J Ngeh, L Nicolas Chialvo, T Nieminen, M Nikkanen, J Nikl, M Nikoforova, S Nishino, Y Nishiyama, X Njovane, S Nogawa, F Nombela, B Norrving, K Nosek, B Nowak, E Nowakowska-Sledz, G Ntaios, H Numminen, F Nunez, M Obadia, S Oberndorfer, A Obrezan, J Ochiai, W Oczkowski, MJ O'Donnell, A Odyniec, K Oh, M Ohira, Y Okamoto, M Okpala, S Okubo, L Olah, V Olavarria, J Oleszek, N Onat Demirci, V Ondar, G Ongun, K Ooyama, V Orosz, R Ortiz, G Osseby, E Österlund-Tauriala, C Ovesen, S Ozcekic Demirhan, J Ozdoba-Rot, S Ozturk, E Ozyurt, M Pablo Grecco, G Pablo Povedano, M Paciaroni, C Padiglioni, J Pagola, W Palasik, G Panczel, L Panos, G Papadopoulos, E Papadopoulou, A Papagiannis, V Papavasileiou, M Papina, JR Pardo De Donlebun, V Parisi, JM Park, J Pasten, N Patel, O Pavlik, M Pawelczyk, WF Peacock, H Pei, T Peisker, LF Pena Sedna, A Penn, S Pentek, E Pepper, L Pereira, K Perera, Y Perez, S Perez, P Perez Leguizamon, M Pernicka, R Perry, A Persico, Y Pesant, S Peska, D Peters, G Peters, L Pettigrew, T Phan, S Philippi, T Phinney, F Pico, A Pidal, B Piechowski-Jozwiak, A Pieroni, S Pineiro, V Piras, N Pizova, J Polanco, M Polin, A Polyakov, E Polychronopoulou, A Polymeris, D Popov, A Poppe, P Postorino, C Pozzerese, M Pradhan, L Prats, E Prazdnichkova, B Prendl, M Pretorius, P Profice, S Prokopenko, E Pudov, V Pujol Lereis, G Punzo Bravo, F Purroy, J Qiu, X Qu, V Quenardelle, H Quesada Garcia, L Radrizzani, A Radtke, T Raffelsberger, JM Ramirez Moreno, C Ramos-Estebanez, A Rani, P Rapantova, K Rashed, A Rasheed Nihara, J Rasmussen, L Redondo Robles, M Reif, P Reiner, P Rekova, A Renu, M Repetto, P Reyes, S Reyes Morales, JH Rha, J Ribeiro, S Ricci, C Richard, R Rigual, C Rinaldi, C Riveira Rodriguez, B Rizzato, TG Robinson, A Rocco, M Rodrigues, G Rodriguez, A Rodriguez Campello, F Rodriguez Lucci, M Rodriguez Yanez, C Roesler, C Roffe, R Roine, S Roine, A Roldan, F Romana Pezzella, M Romano, JS Roos, C Rosso, C Rostrup Kruuse, Y Roth, R Roukens, L Roveri, D Rozanski, J Rozniecki, C Rozsa, S Rudilosso, G Ruiz Ares, A Ruiz Franco, G Rum, J Ruuskanen, I Rybinnik, K Ryota, J Saarinen, V Saavedra, C Sabben, A Sabet, D Sagris, J Sahlas, N Sakai, P Salamanca, P Salgado, S Salig, T Salletmayr, M Salnikov, O Samoshkina, Y Samson, D Sanak, M Sànchez Cerón, P Santalucia, M Santamaria Cadavid, P Santiago, G Santo, B Sanz Cuesta, J Sargento, A Sarraj, K Sas, A Sas, O Satoshi, S Satsoglou, N Sattar, S Savitz, C Savopoulos, J Saw, M Sawicka, R Sawyer, T Scandura, N Schillinger, J Schindler, F Schlachetzki, I Schneider, R Schuppner, J Schurig, CJ Schwarzbach, M Sebejova, G Seidel, L Sekaran, D Selcuk, J Selvarajah, A Semerano, J Semjen, D Semushina, S Sen, M Seok Park, J Serena, O Serhat Tokgoz, W Serles, F Serrano, M Sevin, L Seynaeve, S Shah, N Shamalov, T Shang, M Sharma, A Sharrief, M Shazam Hussain, I Shchukin, W Shen, E Shepeleva, I Shinsuke, A Shmonin, A Shoamanesh, A Shuaib, A Shulga, G Sibolt, I Sibon, I Sicilia, M Siebert, E Sieczkowska, C Sila, AA Silva, D Silva, P Silva, Y Silva, M Silvestrini, Z Simony, A Simpkins, B Singh, D Sinha, I Sipos, O Skoda, P Skowron, M Skowronska, B Sliwinska, J Slonkova, A Smolkin, A Smyth, P Sobolewski, A Sobota, SI Sohn, M Soldatov, I Solganov, L Soloveva, E Solovyeva, N Sonntag, P Soors, M Sorgun, C Soriano, D Spence, K Spengos, L Sposato, G Staaf, K Stadler, L Stakhovskaya, K Stamatelopoulos, S Steinert, I Stetkarova, M Stiehm, R Stocker, J Stoinski, A Stoll, G Stotts, A Stumpp, P Sucapane, T Suenaga, X Sun, S Sundararajan, J Sung Kim, H Suzuki, N Svaneborg, G Szasz, W Szczuchniak, S Szczyrba, N Szegedi, A Szekely, Z Szewczyk, G Szilagyi, S Szlufik, K Szoboszlai, L Szpisjak, R Sztajzel, L Sztriha, SE Ta Wil, J Taggeselle, K Takamatsu, M Takao, W Taki, S Takizawa, M Talahma, A Tamayo, J Tan, D Tanne, A Tapanainen, T Tapiola, J Tarasiuk, T Tatlisumak, A Tayal, S Tcvetkova, P Teal, J Tejada Garcia, H Tejada Meza, D Tenora, M Terceno, A Terentiou, S Tezcan, D Thaler, A Thomson, E Thouvenot, M Tiainen, I Timberg, S Timsit, A Tinchon, D Tirschwell, C Togay Isikay, K Tokunaga, M Tolino, C Toloza, G Tomelleri, K Tomoyuki, LM Tomppo, Z Tong, L Tong, D Toni, J Torres, C Tossavainen, G Toth, A Tountopoulou, E Touze, M Tovar, K Toyoda, S Trillo, A Trommer, D Tropepi, D Tryambake, H Tu, S Tuetuencue, R Tumova, O Tumpula, G Turc, A Tutaj, J Tynkkynen, S Uchiyama, U Uchwat, L Uhrinyakova, R Ulku Acar, D Uluduz Ugurlu, X Urra, S Urui, M Usero Ruiz, D Vaclavik, K Vahedi, A Valikovics, J Valpas, P Van Acker, W Van Daele, G Vanderschueren, L Vanina Jure, R Varela, Z Varga, J Varvat, N Varvyanskaya, A Vasco Salgado, P Vasko, L Vass, S Vassilopoulou, I Vastagh, P Vazquez, L Vecsei, R Veltkamp, M Venti, M Verdugo, V Verocai, M Veronica Marroquin, C Veronica Simonsini, T Veverka, M Vigl, A Vila, C Vilar, JA Villanueva Osorio, J Virta, E Vitkova, B Voglsperger, J Volna, PA Von Weitzel-Mudersbach, N Vora, I Voznyuk, A Wach-Klink, A Wacongne, D Walters, Y Wang, J Wang, L Wang, X Wang, W Wang, N Wang, D Wang, H Wang, W Warnack, K Wartenberg, R Waters, M Waters, T Webb, J Weber, G Weiss, K Weissenborn, JI Weitz, B Weller, G Wen, G Weng, P Werner, D Werring, P Wester, W Whiteley, R Whiting, T Wijeratne, C Willems, L Wilson, C Wilson, T Winder, J Windt, A Winkler, A Winska-Tereszkiewicz, A Wisniewska, M Wittayer, A Wlodek, A Wojnarowska-Arendt, M Wolf, V Wolff, C Wolter, A Wong, H Wook Nah, H Worthmann, W Wu, S Wu, S Wunderlich, H Wurzinger, DG Wyse, B Xiao, W Xiaopeng, A Ximenez-Carrillo, L Xiong, Y Xiong, W Xiong, Y Xu, J Xu, Z Xu, B Yalo, T Yamada, M Yamasaki, L Yang, Y Yang, X Yang, Q Yang, B Yang, J Yang, I Yasuhiro, M Yee Lam, C Yegappan, S Yip, E Ylikallio, P Ylikotila, A Yongwon Jin, BW Yoon, Y Yoshida, L Yperzeele, H Yuan, H Yuasa, J Zalewska, C Zanferrari, E Zapata, D Zboznovits, I Zelenka, C Zhang, B Zhang, S Zhang, M Zhang, X Zhang, J Zhang, L Zhao, O Zhirnova, L Zhou, J Zielinska-Turek, I Zinchenko, M Ziomek, A Zitzmann, R Zweifler, J Zwiernik, Yperzeele, Laetitia, and NAVIGATE ESUS Investigators
- Subjects
Male ,International Cooperation ,030204 cardiovascular system & hematology ,antiplatelet therapy ,law.invention ,Neurology (clinical) ,ischemic stroke ,anticoagulation ,Cohort Studies ,0302 clinical medicine ,Randomized controlled trial ,Rivaroxaban ,law ,Stroke ,education.field_of_study ,Aspirin ,Anticoagulant ,Settore BIO/14 ,Middle Aged ,3. Good health ,Treatment Outcome ,N/A ,Cardiology ,Platelet aggregation inhibitor ,Settore MED/26 - Neurologia ,Female ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,MEDLINE ,Population ,Foramen Ovale, Patent ,Subgroup analysis ,Article ,Statistics, Nonparametric ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,medicine ,Humans ,education ,Aged ,business.industry ,medicine.disease ,Human medicine ,business ,030217 neurology & neurosurgery ,Platelet Aggregation Inhibitors ,Factor Xa Inhibitors - Abstract
Background: \ud Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial.\ud \ud Methods: \ud NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy.\ud \ud Findings: \ud Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity.\ud \ud Interpretation: \ud Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted.\ud \ud Funding: \ud Bayer and Janssen.
- Published
- 2018
45. Risk of Soft-Tissue Sarcoma Among 69 460 Five-Year Survivors of Childhood Cancer in Europe
- Author
-
Nadia Haddy, Melanie Kaiser, Daniela Alessi, Riccardo Haupt, Jop C Teepen, Leontien C.M. Kremer, Peter Kaatsch, Momcilo Jankovic, David L. Winter, Francesca Bagnasco, Lorna Zadravec Zaletel, Elizabeth A M Feijen, Florent de Vathaire, Joyeeta Guha, Giao Vu-Bezin, Thomas Wiebe, Helena M. Linge, Lars Hjorth, Zsuzsanna Jakab, Claudia E. Kuehni, Edit Bardi, Andrea Bautz, Michael M. Hawkins, Jeanette Falck Winther, Cécile M. Ronckers, Thorgerdur Gudmundsdottir, Roderick Skinner, Stanislaw Garwicz, Monica Terenziani, Raoul C. Reulen, Finn Wesenberg, Julianne Byrne, Desiree Grabow, Rodrigue S. Allodji, Hilde Øfstaas, Rahel Kuonen, Miranda M. Fidler, Chloe J Bright, Carlotta Sacerdote, Päivi M. Lähteenmäki, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, and Graduate School
- Subjects
Oncology ,Male ,Cancer Research ,Time Factors ,2ND MALIGNANCIES ,Soft Tissue Neoplasms ,Cohort Studies ,0302 clinical medicine ,Cancer Survivors ,Risk Factors ,030212 general & internal medicine ,Registries ,Sarcoma/epidemiology ,Child ,education.field_of_study ,BRITAIN ,Incidence (epidemiology) ,Incidence ,Absolute risk reduction ,Neoplasms, Second Primary ,Sarcoma ,Middle Aged ,CHEMOTHERAPY ,TUMORS ,3. Good health ,Europe ,030220 oncology & carcinogenesis ,Child, Preschool ,Cohort ,Female ,HEREDITARY RETINOBLASTOMA ,Cohort study ,Cancer Survivors/statistics & numerical data ,RADIOTHERAPY ,NEOPLASMS ,Leiomyosarcoma ,Adult ,medicine.medical_specialty ,Adolescent ,Population ,610 Medicine & health ,Europe/epidemiology ,03 medical and health sciences ,Young Adult ,Soft Tissue Neoplasms/epidemiology ,360 Social problems & social services ,Internal medicine ,medicine ,Humans ,SECONDARY SARCOMAS ,education ,business.industry ,Infant, Newborn ,Infant ,Wilms' tumor ,medicine.disease ,Neoplasms, Second Primary/epidemiology ,business ,Follow-Up Studies - Abstract
Background: Childhood cancer survivors are at risk of subsequent primary soft-tissue sarcomas (STS), but the risks of specific STS histological subtypes are unknown. We quantified the risk of STS histological subtypes after specific types of childhood cancer.Methods: We pooled data from 13 European cohorts, yielding a cohort of 69 460 five-year survivors of childhood cancer. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated.Results: Overall, 301 STS developed compared with 19 expected (SIR = 15.7, 95% confidence interval [CI] = 14.0 to 17.6). The highest standardized incidence ratios were for malignant peripheral nerve sheath tumors (MPNST; SIR = 40.6, 95% CI = 29.6 to 54.3), leiomyosarcomas (SIR = 29.9, 95% CI = 23.7 to 37.2), and fibromatous neoplasms (SIR = 12.3, 95% CI = 9.3 to 16.0). SIRs for MPNST were highest following central nervous system tumors (SIR = 80.5, 95% CI = 48.4 to 125.7), Hodgkin lymphoma (SIR = 81.3, 95% CI = 35.1 to 160.1), and Wilms tumor (SIR = 76.0, 95% CI = 27.9 to 165.4). Standardized incidence ratios for leiomyosarcoma were highest following retinoblastoma (SIR = 342.9, 95% CI = 245.0 to 466.9) and Wilms tumor (SIR = 74.2, 95% CI = 37.1 to 132.8). AERs for all STS subtypes were generally low at all years from diagnosis (AER < 1 per 10 000 person-years), except for leiomyosarcoma following retinoblastoma, for which the AER reached 52.7 (95% CI = 20.0 to 85.5) per 10 000 person-years among patients who had survived at least 45 years from diagnosis of retinoblastoma.Conclusions: For the first time, we provide risk estimates of specific STS subtypes following childhood cancers and give evidence that risks of MPNSTs, leiomyosarcomas, and fibromatous neoplasms are particularly increased. While the multiplicative excess risks relative to the general population are substantial, the absolute excess risk of developing any STS subtype is low, except for leiomyosarcoma after retinoblastoma. These results are likely to be informative for both survivors and health care providers.
- Published
- 2018
46. Reducing Social Inequalities in Cancer: Setting Priorities for Research
- Author
-
Miranda M. Fidler, David I. Conway, Diana Sarfati, Salvatore Vaccarella, Christopher P. Wild, Rodolfo Saracci, Ahmedin Jemal, Kurt Straif, Johan P. Mackenbach, Michael Marmot, Joannie Lortet-Tieulent, Nadia Vilahur, and Public Health
- Subjects
medicine.medical_specialty ,Biomedical Research ,business.industry ,Health Priorities ,MEDLINE ,Cancer ,Neoplasms therapy ,Hematology ,Health Status Disparities ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,SDG 3 - Good Health and Well-being ,Socioeconomic Factors ,030220 oncology & carcinogenesis ,Family medicine ,Neoplasms ,medicine ,Humans ,Social inequality ,030212 general & internal medicine ,Healthcare Disparities ,business - Published
- 2018
47. Young adults: a unique group in cancer epidemiological research - Authors' reply
- Author
-
Isabelle Soerjomataram, Freddie Bray, Jacques Ferlay, Miranda M. Fidler, Sumit Gupta, and Eva Steliarova-Foucher
- Subjects
0301 basic medicine ,Gerontology ,Adult ,medicine.medical_specialty ,business.industry ,Research ,Cancer ,medicine.disease ,03 medical and health sciences ,Young Adult ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Neoplasms ,Epidemiology ,medicine ,Humans ,Young adult ,business - Published
- 2018
48. Risk of Subsequent Bone Cancers Among 69 460 Five-Year Survivors of Childhood and Adolescent Cancer in Europe
- Author
-
David L. Winter, Leontien C.M. Kremer, Joyeeta Guha, Päivi M. Lähteenmäki, Helena M. Linge, Giao Vu-Bezin, Zsuzsanna Jakab, Michael M. Hawkins, Jeanette Falck Winther, Miranda M. Fidler, Stanislaw Garwicz, Raoul C. Reulen, Roderick Skinner, Desiree Grabow, Riccardo Haupt, Edit Bardi, Finn Wesenberg, Thorgerdur Gudmundsdottir, Lorna Zadravec Zaletel, Andrea Bautz, Rahel Kuonen, Jop C Teepen, Franco Merletti, Elizabeth A M Feijen, Rodrigue S. Allodji, Peter Kaatsch, Monica Terenziani, Nadia Haddy, Milena Maule, Cécile M. Ronckers, Melanie Kaiser, Lars Hjorth, Momcilo Jankovic, Florent de Vathaire, Thomas Wiebe, Francesca Bagnasco, Claudia E. Kuehni, Chloe J Bright, Julianne Byrne, Hilde Øfstaas, CCA - Cancer Treatment and Quality of Life, Paediatric Oncology, Graduate School, and ARD - Amsterdam Reproduction and Development
- Subjects
Male ,0301 basic medicine ,Cancer Research ,Pediatrics ,Cohort Studies ,0302 clinical medicine ,Retinoblastoma/epidemiology ,Neoplasms ,Sarcoma/epidemiology ,Survivors ,Young adult ,Child ,610 Medicine & health ,Osteosarcoma ,education.field_of_study ,Soft tissue sarcoma ,Retinoblastoma ,Neoplasms, Second Primary ,Sarcoma ,Survivors/statistics & numerical data ,Europe ,Second Primary ,Oncology ,Osteosarcoma/epidemiology ,030220 oncology & carcinogenesis ,Adolescent ,Adult ,Bone Neoplasms ,Female ,Follow-Up Studies ,Humans ,Young Adult ,360 Social problems & social services ,medicine.medical_specialty ,Population ,Bone Sarcoma ,Europe/epidemiology ,03 medical and health sciences ,medicine ,education ,Gynecology ,business.industry ,Cancer ,ta3122 ,medicine.disease ,030104 developmental biology ,Primary bone ,Relative risk ,Bone Neoplasms/epidemiology ,Neoplasms, Second Primary/epidemiology ,business - Abstract
Introduction: We investigate the risks of subsequent primary bone cancers after childhood and adolescent cancer in 12 European countries. For the first time, we satisfactorily address the risks beyond 40 years from diagnosis and beyond 40 years of age among all survivors.Methods: This largest-ever assembled cohort comprises 69 460 five-year survivors of cancer diagnosed before age 20 years. Standardized incidence ratios, absolute excess risks, and multivariable-adjusted relative risks and relative excess risks were calculated. All statistical tests were two-sided.Results: Overall, survivors were 21.65 times (95% confidence interval = 18.97 to 24.60 times) more likely to be diagnosed with a subsequent primary bone cancer than expected from the general population. The greatest excess numbers of bone cancers were observed after retinoblastoma, bone sarcoma, and soft tissue sarcoma. The excess number of bone cancers declined linearly with both years since diagnosis and attained age (all P < .05). Beyond 40 years from diagnosis and age 40 years, there were at most 0.45 excess bone cancers among all survivors per 10 000 person-years at risk; beyond 30 years from diagnosis and age 30 years, there were at most 5.02 excess bone cancers after each of retinoblastoma, bone sarcoma, and soft tissue sarcoma, per 10 000 person-years at risk.Conclusions: For all survivors combined and the cancer groups with the greatest excess number of bone cancers, the excess numbers observed declined with both age and years from diagnosis. These results provide novel, reliable, and unbiased information about risks and risk factors among long-term survivors of childhood and adolescent cancer.
- Published
- 2018
- Full Text
- View/download PDF
49. The PanCareSurFup consortium: research and guidelines to improve lives for survivors of childhood cancer
- Author
-
Helena M. Linge, Eva Frey, Lorna Zadravec Zaletel, David L. Winter, Daniela Alessi, Rahel Kuonen, Leontien C.M. Kremer, Rodrigue S. Allodji, Carlotta Sacerdote, Thomas Wiebe, Cécile M. Ronckers, Renée L. Mulder, Roderick Skinner, Gill Levitt, Giao Vũ Bezin, Gisela Michel, Finn Wesenberg, Andrea Bautz, Raoul C. Reulen, Melanie Kaiser, Ibrahima Diallo, Momcilo Jankovic, Desiree Grabow, Stanislaw Garwicz, Thorgerdur Gudmundsdottir, Riccardo Haupt, Florent de Vathaire, Damien Llanas, Peter Kaatsch, Elizabeth A M Feijen, Elise Witthoff, Edit Bardi, Jeanette Falck Winther, Eva Steliarova-Foucher, Francesca Bagnasco, Chloe J Bright, Oskar Hagberg, Julianne Byrne, Claudia E. Kuehni, Zsuzsanna Jakab, Lars Hjorth, Vera Morsellino, Eva M Hau, Miranda M. Fidler, Päivi M. Lähteenmäki, Morven C. Brown, Ruth Ladenstein, Arja Harila-Saari, Michael M. Hawkins, Helena J H van der Pal, ARD - Amsterdam Reproduction and Development, Paediatric Oncology, CCA - Cancer Treatment and Quality of Life, and APH - Quality of Care
- Subjects
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi ,Male ,Cancer Research ,medicine.medical_specialty ,Childhood and adolescent cancer ,Biomedical Research ,Adolescent cancer ,Childhood cancer ,Guidelines as Topic ,Pilot Projects ,Disease ,Guidelines ,Health outcomes ,030218 nuclear medicine & medical imaging ,Late mortality ,03 medical and health sciences ,0302 clinical medicine ,Second malignancies ,Neoplasms ,medicine ,Humans ,Pooled data ,Survivors ,Intensive care medicine ,Child ,Cardiac late effects ,business.industry ,Cancer ,Health Care Service and Management, Health Policy and Services and Health Economy ,medicine.disease ,3. Good health ,Increased risk ,Oncology ,030220 oncology & carcinogenesis ,Cohort ,Feasibility Studies ,Female ,business - Abstract
Background: Second malignant neoplasms and cardiotoxicity are among the most serious and frequent adverse health outcomes experienced by childhood and adolescent cancer survivors (CCSs) and contribute significantly to their increased risk of premature mortality. Owing to differences in health-care systems, language and culture across the continent, Europe has had limited success in establishing multi-country collaborations needed to assemble the numbers of survivors required to clarify the health issues arising after successful cancer treatment. PanCareSurFup (PCSF) is the first pan-European project to evaluate some of the serious long-term health risks faced by survivors. This article sets out the overall rationale, methods and preliminary results of PCSF. Methods: The PCSF consortium pooled data from 13 cancer registries and hospitals in 12 European countries to evaluate subsequent primary malignancies, cardiac disease and late mortality in survivors diagnosed between ages 0 and 20 years. In addition, PCSF integrated radiation dosimetry to sites of second malignancies and to the heart, developed evidence-based guidelines for long-term care and for transition services, and disseminated results to survivors and the public. Results: We identified 115,596 individuals diagnosed with cancer, of whom 83,333 were 5-year survivors and diagnosed from 1940 to 2011. This single data set forms the basis for cohort analyses of subsequent malignancies, cardiac disease and late mortality and case–control studies of subsequent malignancies and cardiac disease in 5-year survivors. Conclusions: PCSF delivered specific estimates of risk and comprehensive guidelines to help survivors and care-givers. The expected benefit is to provide every European CCS with improved access to care and better long-term health.
- Published
- 2018
- Full Text
- View/download PDF
50. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991–2010 (Automated Childhood Cancer Information System): a population-based study
- Author
-
Giovanna Tagliabue, Michel Velten, Stefano Ferretti, Giske Ursin, Staffan Khan, Ceri White, Marc Colonna, Xavier Troussard, Alain Monnereau, José Ramón Quirós Garcia, Brigitte Lacour, Zdravka Valerianova, Isabelle Soerjomataram, Marisa L. Vicente Raneda, Lucia Mangone, Laufey Tryggvadottir, Freddie Bray, Anna Zborovskaya, Anastasia Dolya, Christine Bouchardy, Brigitte Trétarre, Maria Ramos Monserrat, Franco Merletti, Rafael Marcos-Gragera, Enrique Almar Marqués, Fabio Falcini, Isabelle Konzelmann, Anne Sophie Woronoff, Bianca Caruso, Margit Mägi, David H. Brewster, Charles A. Stiller, Ryszard Mężyk, Sally Vernon, Rafael Peris-Bonet, Olivier Ganry, Eva Steliarova-Foucher, Marion Piñeros, Peter Kaatsch, Miranda M. Fidler, Jacqueline Clavel, Rafael Fernández-Delgado, Fabio Levi, Claudia E. Kuehni, Rosario Tumino, Eva Ardanaz, Arantza Lopez de Munain, Otto Visser, Murielle Colombet, Berndt Holleczek, Jan Willem Coebergh, José Laranja Pontes, Maja Primic Žakelj, Zsuzsanna Jakab, Jaume Galceran, Nadya Dimitrova, Pascale Grosclaude, Roberto Zanetti, Kamila Kepska, A.V. Guizard, Sabine Rohrmann, Véronique Bouvier, Ladislav Dušek, Emilie Marrer, Maria Michiara, Maria Jose Sanchez-Perez, Monika Hackl, University of Zurich, Steliarova-Foucher, Eva, ACCIS contributors, Hackl, M., Zborovskaya, A., Dimitrova, N., Valerianova, Z., Dušek, L., Mägi, M., Monnereau, A., Clavel, J., Velten, M., Guizard, A.V., Bouvier, V., Troussard, X., Woronoff, A.S., Marrer, E., Trétarre, B., Colonna, M., Ganry, O., Grosclaude, P., Holleczek, B., Jakab, Z., Tryggvadóttir, L., Mangone, L., Merletti, F., Ferretti, S., Caruso, B., Michiara, M., Tumino, R., Falcini, F., Zanetti, R., Tagliabue, G., Visser, O., Ursin, G., Mężyk, R., Kepska, K., Laranja Pontes, J., Primic Žakelj, M., Fernández-Delgado, R., Vicente Raneda, M.L., Almar Marqués, E., Quirós Garcia, J.R., Lopez de Munain, A., Marcos-Gragera, R., Sanchez-Perez, M.J., Ramos Monserrat, M., Ardanaz, E., Galceran, J., Khan, S., Kuehni, C.E., Bouchardy, C., Levi, F., Konzelmann, I., Rohrmann, S., Vernon, S., Brewster, D.H., White, C., Dolya, A., and Public Health
- Subjects
Male ,Càncer en els infants ,Time Factors ,Cancer in children ,0302 clinical medicine ,Risk Factors ,Neoplasms ,030212 general & internal medicine ,Registries ,Age of Onset ,Child ,media_common ,education.field_of_study ,Cancer in adolescence ,Incidence (epidemiology) ,Incidence ,3. Good health ,Europe ,Oncology ,030220 oncology & carcinogenesis ,Regional studies ,Child, Preschool ,Female ,2730 Oncology ,Adolescent ,Population ,Childhood cancer ,Socio-culturale ,610 Medicine & health ,Risk Assessment ,Article ,03 medical and health sciences ,Young Adult ,Age Distribution ,SDG 3 - Good Health and Well-being ,medicine ,media_common.cataloged_instance ,Humans ,Càncer en els adolescents ,European union ,education ,business.industry ,Infant, Newborn ,Cancer ,Infant ,Health Status Disparities ,10060 Epidemiology, Biostatistics and Prevention Institute (EBPI) ,medicine.disease ,Population based study ,Cancer incidence ,business ,Demography - Abstract
List of ACCIS contributors = Monika Hackl, Anna Zborovskaya, Nadya Dimitrova, Zdravka Valerianova, Ladislav Dušek, Margit Mägi, Alain Monnereau, Jacqueline Clavel, Michel Velten, Anne-Valérie Guizard, Véronique Bouvier, Xavier Troussard, Anne-Sophie Woronoff, Emilie Marrer, Brigitte Trétarre, Marc Colonna, Olivier Ganry, Pascale Grosclaude, Berndt Holleczek, Zsuzsanna Jakab, Laufey Tryggvadóttir, Lucia Mangone, Franco Merletti, Stefano Ferretti, Bianca Caruso, Maria Michiara, Rosario Tumino, Fabio Falcini, Roberto Zanetti, Giovanna Tagliabue, Otto Visser, Giske Ursin, Ryszard Mężyk, Kamila Kepska, José Laranja Pontes, Maja Primic Žakelj, Rafael Fernández-Delgado, Marisa L Vicente Raneda, Enrique Almar Marqués, José Ramón Quirós Garcia, Arantza Lopez de Munain, Rafael Marcos-Gragera, Maria-Jose Sanchez-Perez, Maria Ramos Monserrat, Eva Ardanaz, Jaume Galceran, Staffan Khan, Claudia E Kuehni Christine Bouchardy, Fabio Levi, Isabelle Konzelmann, Sabine Rohrmann Sally Vernon, David H Brewster, Ceri White, Anastasia Dolya Background A deceleration in the increase in cancer incidence in children and adolescents has been reported in several national and regional studies in Europe. Based on a large database representing 1∙3 billion person-years over the period 1991–2010, we provide a consolidated report on cancer incidence trends at ages 0–19 years. Methods We invited all population-based cancer registries operating in European countries to participate in this population-based registry study. We requested a listing of individual records of cancer cases, including sex, age, date of birth, date of cancer diagnosis, tumour sequence number, primary site, morphology, behaviour, and the most valid basis of diagnosis. We also requested population counts in each calendar year by sex and age for the registration area, from official national sources, and specific information about the covered area and registration practices. An eligible registry could become a contributor if it provided quality data for all complete calendar years in the period 1991–2010. Incidence rates and the average annual percentage change with 95% CIs were reported for all cancers and major diagnostic groups, by region and overall, separately for children (age 0–14 years) and adolescents (age 15–19 years). We examined and quantified the stability of the trends with joinpoint analyses. Findings For the years 1991–2010, 53 registries in 19 countries contributed a total of 180335 unique cases. We excluded 15162 (8·4%) of 180335 cases due to differing practices of registration, and considered the quality indicators for the 165173 cases included to be satisfactory. The average annual age-standardised incidence was 137∙5 (95% CI 136∙7–138∙3) per million person-years and incidence increased significantly by 0∙54% (0∙44–0∙65) per year in children (age 0–14 years) with no change in trend. In adolescents, the combined European incidence was 176∙2 (174∙4–178∙0) per million person-years based on all 35138 eligible cases and increased significantly by 0·96% (0∙73–1∙19) per year, although recent changes in rates among adolescents suggest a deceleration in this increasing trend. We observed temporal variations in trends by age group, geographical region, and diagnostic group. The combined age-standardised incidence of leukaemia based on 48458 cases in children was 46∙9 (46∙5–47∙3) per million person-years and increased significantly by 0∙66% (0∙48–0∙84) per year. The average overall incidence of leukaemia in adolescents was 23∙6 (22∙9–24∙3) per million person-years, based on 4702 cases, and the average annual change was 0∙93% (0∙49–1∙37). We also observed increasing incidence of lymphoma in adolescents (average annual change 1·04% [0·65–1·44], malignant CNS tumours in children (average annual change 0·49% [0·20–0·77]), and other tumours in both children (average annual change 0·56 [0·40–0·72]) and adolescents (average annual change 1∙17 [0∙82–1∙53]). Interpretation Improvements in the diagnosis and registration of cancers over time could partly explain the observed increase in incidence, although some changes in underlying putative risk factors cannot be excluded. Cancer incidence trends in this young population require continued monitoring at an international level. Funding Federal Ministry of Health of the Federal German Government, the European Union’s Seventh Framework Programme, and International Agency for Research on Cancer
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.